Document:

Exhibit
10.1

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY                  ,
HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL

 

Execution
Version

 

CONFIDENTIAL

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOAN
AGREEMENT

 

Dated
as of April 26, 2022

 

between

 

Merqueo
S.A.S.,

as Borrower

 

and

 

Blue
like an Orange Sustainable Capital - Latin America Holdings II S.A.R.L., as lender

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

CONFIDENTIAL

TABLE
OF CONTENTS

 

	ARTICLE
    1 Definitions; Interpretation	1
	 	Section 1.1	Definitions	1
	 	Section 1.2	Interpretation	1
	 	Section 1.3	Business Day Adjustment	2
	 	Section 1.4	Financial Calculations	2
	 	Section 1.5	BlaO’s Calculation or Determination Final	2
	 	 	 	 
	ARTICLE
    2 Part 1: The BlaO Loan	2
	 	Section 2.1	The BlaO Loan	2
	 	Section 2.2	Disbursement Procedure	2
	 	Section 2.3	Repayment	3
	 	Section 2.4	Voluntary and Mandatory Prepayments	3
	 	Section 2.5	Application of Prepayments	5
	 	Section 2.6	Currency and Place of Payment	5
	 	Section 2.7	Allocation of Partial Payments	6
	 	Section 2.8	Default Interest	6
	 	Section 2.9	Taxes	6
	 	Section 2.10	Suspension of Disbursements; Cancellation of BlaO Loan Commitment	7
	 	Section 2.11	Illegality	7
	 	Section 2.12	Payment of Fees, Costs and Expenses	8
	 	 	 	 
	Part 2: Interest Rate Terms and Conditions	10
	 	Section 2.13	BlaO Loan Interest	10
	 	Section 2.14	Additional Interest	10
	 	Section 2.15	Market Disruption	11
	 	Section 2.16	Benchmark Replacement Setting	12
	 	 	 	 
	Part 3: Promissory Notes	13
	 	Section 2.17	Notes	13
	 	 	 	 
	ARTICLE
    3 Representations and Warranties	13
	 	Section 3.1	Representations and Warranties	13
	 	Section 3.2	Acknowledgment and Warranty	17
	 	 	 	 
	ARTICLE
    4 Conditions Precedent to Disbursement	17
	 	Section 4.1	Conditions Precedent to First Disbursement	17
	 	Section 4.2	Conditions Precedent to Second Disbursement	18
	 	Section 4.3	Conditions Precedent to All Disbursements	19
	 	 	 	 
	ARTICLE
    5 Covenants	20
	 	Section 5.1	Affirmative Covenants	20
	 	Section 5.2	Negative Covenants	24
	 	Section 5.3	Information	26
	 	Section 5.4	Environmental and Social	28
	 	 	 	 
	ARTICLE
    6 Events of Default	28
	 	Section 6.1	Events of Default	28
	 	Section 6.2	Remedies	30
	 	Section 6.3	Bankruptcy	30

 

    - i -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

	ARTICLE
    7 Miscellaneous	31
	 	Section 7.1	Notices	31
	 	Section 7.2	English Language	31
	 	Section 7.3	Indemnity; Waiver of Consequential Damages	32
	 	Section 7.4	Successors and Assigns	32
	 	Section 7.5	Counterparts	33
	 	Section 7.6	Confidential Information	33
	 	Section 7.7	Amendment	33
	 	Section 7.8	Savings of Rights; Remedies; No Waiver	33
	 	Section 7.9	Severability	34
	 	Section 7.10	Applicable Law and Jurisdiction	34
	 	Section 7.11	Set-Off	36
	 	Section 7.12	Entire Agreement	36
	 	Section 7.13	No Third-Party Beneficiary	36
	 	Section 7.14	Survival	36
	 	Section 7.15	Term of Agreement	36

 

ANNEXES,
SCHEDULES AND EXHIBITS

 

ANNEXES

 

	ANNEX
    1:	DEFINITIONS
	ANNEX
    2:	ENVIRONMENTAL
    AND SOCIAL PROVISIONS

 

SCHEDULES

 

	SCHEDULE
    1:	MEMBER
    COUNTRIES OF IDB INVEST
	SCHEDULE
    2:	LIST
    OF EXCLUDED ACTIVITIES
	SCHEDULE
    3:	IMPACT
    & SUSTAINABILITY INDICATORS
	SCHEDULE
    3.1.4	RELEVANT
    AUTHORIZATIONS APPLICABLE FOR MERQUEO BRAZIL AND MERQUEO MEXICO
	SCHEDULE
    4:	PERMITTED
    LIENS 
	SCHEDULE
    5:	WAREHOUSE
    LEASES
	SCHEDULE
    6:	BORROWER’S
    SHARE CAPITAL
	SCHEDULE
    7:	KEY
    PERFORMANCE INDICATORS
	SCHEDULE
    8:	CORPORATE
    GOVERNANCE ACTION PLAN

 

EXHIBITS

 

	EXHIBIT
    1:	FORM
    OF DISBURSEMENT REQUEST
	EXHIBIT
    2:	FORM
    OF BORROWER’S CERTIFICATE REGARDING ORGANIZATIONAL DOCUMENTS/CORPORATE RESOLUTIONS
	EXHIBIT
    3:	FORM
    OF BORROWER’S SERVICE OF PROCESS LETTER 
	EXHIBIT
    4:	FORM
    OF AUTHORIZATION TO AUDITOR
	EXHIBIT
    5:	FORM
    OF BORROWER’S CERTIFICATE OF INCUMBENCY AND AUTHORITY
	EXHIBIT
    6:	FORM
    OF BORROWER’S QUARTERLY CERTIFICATE 
	EXHIBIT
    7:	FINANCIAL
    RATIOS COMPLIANCE CERTIFICATE
	EXHIBIT
    8:	FORM
    OF BORROWER’S LEGAL OPINION

 

    - ii -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

LOAN AGREEMENT
(together with all Annexes, Schedules and Exhibits hereto, this “Agreement”) dated as of April 26, 2022 (the “Effective
Date”), between:

 

		(1)	MERQUEO
                                            S.A.S., a simplified stock corporation organized and existing under the laws of the Republic
                                            of Colombia (the “Borrower”); and

 

		(2)	BLUE
                                            LIKE AN ORANGE SUSTAINABLE CAPITAL - LATIN AMERICA HOLDINGS II S.A.R.L., a Luxembourg
                                            société à responsabilité limitée (“BlaO”),
                                            as lender of the BlaO Loan (as defined below).

 

 

ARTICLE
1

 

Definitions;
Interpretation

 

Section
1.1 Definitions.

 

Capitalized
terms used herein have the meanings provided in Annex 1 (Definitions).

 

Section
1.2 Interpretation.

 

In this Agreement,
unless the context otherwise requires:

 

(i)
headings are for convenience only and do not affect its interpretation;

 

(ii)
singular terms include the plural and vice versa, and each gender includes all genders;

 

(iii)
a reference to an Article, Section, paragraph, Schedule, Exhibit or Annex is a reference to that Article, Section or paragraph of, Schedule,
Exhibit or Annex to, this Agreement, unless otherwise specified;

 

(iv)
a reference to a document includes any amendment or supplement to, or replacement, novation or modification of, that document unless
made in breach of this Agreement;

 

(v)
the term “including” means “including without limitation”;

 

(vi)
the terms “herein,” “hereof” and “hereunder” refer to this Agreement as a whole;

 

(vii)
phrases such as “satisfactory to BlaO”, “approved by BlaO”, “acceptable to BlaO”, “as BlaO
determines”, “selected by BlaO” and phrases of similar import, authorize BlaO to act and/or make the relevant determination
in its sole discretion;

 

(viii)
phrases such as “as BlaO may reasonably require” or “as BlaO may reasonably request” and phrases of similar import
authorize and permit BlaO to act or decline to act in its reasonable discretion;

 

(ix)
references to “knowledge,” “know” and “known” shall mean knowledge after due inquiry and references
to such terms in respect of the Borrower shall be deemed to include the knowledge of the Founders; and

 

(x)
in the computation of periods of time from a specified date to a later specified date, the word “from” means “from
and including” and the words “to” and “until” mean “to but excluding”.

 

    -1-
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Section
1.3 Business Day Adjustment.

 

If
a payment is due on a date that is not a Business Day, such payment shall instead be due on the next succeeding Business Day. Interest,
fees and charges (if any) thereon shall continue to accrue until the date such payment is made.

 

Section
1.4 Financial Calculations.

 

All
financial calculations to be made for the purposes of this Agreement or any other Financing Document shall be determined in accordance
with the Accounting Principles and, except as otherwise required by this Agreement, shall be based on the Borrower’s most recently
issued quarterly Financial Statements furnished to BlaO under Section 5.3.2 (Unaudited Quarterly Financial Statements); provided
however, that where financial calculations would otherwise be based on Financial Statements from the last quarter of a Financial
Year, then, at BlaO’s option, those calculations will instead be based on the audited Financial Statements for the relevant Financial
Year.

 

Section
1.5 BlaO’s Calculation or Determination Final.

 

Any
calculation or determination by BlaO of any amount pursuant to this Agreement, including the Interest Rate, the Additional Interest,
any other fees, Costs and compliance with any Financial Covenants, shall be final and conclusive and bind the Borrower unless the determination
involved manifest error. BlaO’s internal records regarding payments made on account of the Obligations shall be conclusive and
bind the Borrower unless the determination involved manifest error; provided, that the failure of BlaO to maintain such accounts
or any error therein shall not affect the Borrower’s obligation to repay the BlaO Loan in accordance with this Agreement. BlaO
shall not have any liability of any nature whatsoever as a result of any determination made by BlaO being proved to involve any error.

 

ARTICLE
2

 

Part
1: The BlaO Loan

 

Section
2.1 The BlaO Loan.

 

2.1.1
Subject to the terms and conditions of this Agreement, BlaO agrees to lend to the Borrower, and the Borrower agrees to borrow from BlaO,
a loan (the “BlaO Loan”) in an aggregate principal amount of eighteen million Dollars ($18,000,000) (such commitment,
the “BlaO Loan Commitment”).

 

2.1.2
The BlaO Loan shall rank pari passu with the IDB Invest Loan.

 

Section
2.2 Disbursement Procedure.

 

2.2.1
The Borrower may request Disbursements by delivering to BlaO at least ten (10) Business Days prior to each proposed Disbursement Date:
(i) an irrevocable Disbursement Request, appropriately completed and duly executed by an Authorized Representative of the Borrower and
(ii) all documents required to be delivered as a condition precedent to such Disbursement pursuant to Article 4 (Conditions Precedent
to Disbursement) (other than any document that is required to be delivered only as of the relevant Disbursement Date).

 

2.2.2
All Disbursements (other than Disbursements of the Interest Reserve Amount) shall be made in Dollars to the Disbursement Account for
further credit to the bank account of the Borrower in the Borrower’s Country or any other place acceptable to BlaO. Other than
Disbursements of the Interest Reserve Amount which shall be made in accordance with Section 2.2.4 below, the Borrower shall not be permitted
to request more than one (1) Disbursement per month or more than an aggregate of four (4) Disbursements. The first Disbursement shall
be made in a whole Dollar amount of at least eight million Dollars ($8,000,000).

 

    - 2 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

2.2.3
Notwithstanding any other provision of this Agreement, no Disbursement shall be made where a related transfer of funds would violate
any Applicable Law or the AML/CFT policies, procedures or controls of BlaO or any financial institution that is involved in the transfer
of funds.

 

2.2.4
Interest Reserve.

 

(i)
Notwithstanding anything to the contrary in this Agreement:

 

		(a)	during
                                            the period commencing on the first Disbursement Date and ending on the first (1st) anniversary
                                            thereof (the “Interest Reserve Period”), two million Dollars ($2,000,000)
                                            of the BlaO Loan Commitment (the “Interest Reserve Amount”) shall not
                                            be available for Disbursement to the Borrower but instead shall be used to pay interest amounts
                                            owing on the BlaO Loan in accordance with this Section 2.2.4; and

 

		(b)	during
                                            the Interest Reserve Period, BlaO may, at its sole discretion but with notice to the Borrower,
                                            make a Disbursement of all or a portion of the funds in the Interest Reserve Amount directly
                                            to itself in order to pay any amount of interest payable in respect of the BlaO Loan on any
                                            Interest Payment Date (or any other date on which interest becomes payable hereunder, in
                                            connection with a Mandatory Prepayment Event, an Event of Default or otherwise). For the
                                            avoidance of doubt, any such Disbursement shall be added to then-outstanding amount of the
                                            principal of the BlaO Loan.

 

(ii)
After the expiration of the Interest Reserve Period, the Borrower may request a Disbursement of the balance of the Interest Reserve Amount
in accordance with Section 2.2.1 (Disbursement Procedure).

 

Section
2.3 Repayment.

 

2.3.1
The Borrower shall repay the BlaO Loan in Dollars in equal semi-annual installments of principal on each Interest Payment Date commencing
on the First Repayment Date and ending on the Loan Final Maturity Date, on which date the entire remaining outstanding principal amount
of the BlaO Loan shall be due and payable in full.

 

2.3.2
Principal amounts repaid or prepaid may not be re-borrowed.

 

Section
2.4 Voluntary and Mandatory Prepayments.

 

2.4.1
Voluntary Prepayments.

 

(i)
After the third anniversary of the Effective Date, the Borrower may prepay all or any portion of the BlaO Loan on any Interest Payment
Date, upon at least thirty (30) days’ prior irrevocable written notice to BlaO, together with the fees, interest and Costs provided
in Section 2.4.3 (Prepayment Fees and Costs).

 

    - 3 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(ii)
The Borrower may only make a total of two prepayments of the BlaO Loan under this Section 2.4, (a) the first of which shall be in an
amount equal to fifty percent (50%) of the then-outstanding principal balance of the BlaO Loan and (b) the second of which shall be in
an amount equal to the remaining principal balance of the BlaO Loan.

 

(iii)
The Borrower shall deliver to BlaO, prior to the date of prepayment, either (a) evidence satisfactory to BlaO that any Authorizations
necessary for the prepayment have been obtained or (b) a certification that no such Authorizations are required.

 

(iv)
Notwithstanding anything to the contrary in this Section 2.4.1, after the third (3rd) anniversary of the Effective Date, the Borrower
shall not be permitted to make a voluntary prepayment of the BlaO Loan under this Section 2.4.1, unless the Borrower provides evidence
satisfactory to BlaO that the Borrower is making a simultaneous and pro-rated prepayment of the IDB Invest Loan in accordance
with the terms of the IDB Invest Loan Agreement.

 

2.4.2
Mandatory Prepayments. Upon the occurrence of:

 

(i)
Except in the case of a SPAC Transaction, a Change of Control without BlaO’s prior written consent, and in connection therewith
BlaO shall grant or reject any request for such consent within thirty (30) days of the Borrower providing all relevant information reasonably
requested by BlaO; provided, that any failure by BlaO to respond to any such consent request shall be deemed to be a rejection
by BlaO; or

 

(ii)
an Unauthorized Share Transaction (each, a “Mandatory Prepayment Event”),

 

(a)
the Borrower shall prepay all Obligations, including amounts payable with respect to such prepayment pursuant to Section 2.4.3 (Prepayment
Fees and Costs), (b) the BlaO Loan Commitment and the Borrower’s right to request any Disbursements shall be terminated, and
(c) BlaO may exercise any remedies that may be available to BlaO under any Financing Document or Applicable Law. Any prepayment required
by this Section 2.4.2 shall be due and payable no later than ten (10) days following the occurrence of the relevant Mandatory Prepayment
Event.

 

2.4.3
Prepayment Fees and Costs.

 

(i)
Prepayment Fees. With each prepayment of the BlaO Loan pursuant to Section 2.4.1 (Voluntary Prepayments), Section 2.4.2
(Mandatory Prepayments) or otherwise, the Borrower shall concurrently pay a prepayment fee in Dollars which, when added to the
principal amount being prepaid plus all previous installments of principal prepaid or repaid plus all payments of interest,
Additional Interest and fees paid to BlaO in respect of such principal amounts (or deemed allocated to such principal amounts in accordance
with the last sentence of this Section 2.4.3(i)), would yield an amount equal to:

 

		(a)	a
                                            twenty-two percent (22%) IRR on the BlaO Loan (or, in the case of a partial prepayment, the
                                            amount of principal amount being prepaid plus all previous installments of principal
                                            prepaid or repaid), if such prepayment is made on or after the third (3rd) anniversary of
                                            the Effective Date and prior to the fourth (4th) anniversary of the Effective Date;

 

		(b)	a
                                            twenty-one percent (21%) IRR on the BlaO Loan (or, in the case of a partial prepayment, the
                                            amount of principal amount being prepaid plus all previous installments of principal
                                            prepaid or repaid), if such prepayment is made on or after the fourth (4th) anniversary of
                                            the Effective Date and prior to the fifth (5th) anniversary of the Effective Date; or

 

    - 4 -
BlaO Loan Agreement

     

    

  

CONFIDENTIAL

 

		(c)	a
                                            twenty percent (20%) IRR on the BlaO Loan (or, in the case of a partial prepayment, the amount
                                            of principal amount being prepaid plus all previous installments of principal prepaid
                                            or repaid), if such prepayment is made on or after the fifth (5th) anniversary of the Effective
                                            Date;

 

provided,
that if a Mandatory Prepayment Event occurs before the third (3rd) anniversary of the Effective Date, the prepayment fee shall instead
be an amount which would yield a twenty-two percent (22%) IRR assuming a three (3)-year time period; provided further, that in
the case of a Mandatory Prepayment Event under Section 2.4.2(i) where (1) the Borrower requested BlaO’s consent to carry out a
Change of Control in connection with the listing of its or its parent company’s Share Capital on a U.S. securities exchange registered
with the U.S. Securities and Exchange Commission, (2) the Borrower provided to BlaO all relevant information reasonably requested by
it, and (3) BlaO rejected such consent request in respect of the proposed Change of Control, such prepayment fee shall instead be an
amount which would yield a sixteen percent (16%) IRR assuming a three (3)-year time period.

 

For
the avoidance of doubt, the prepayment fee under this Section 2.4.3(i) shall not apply to a prepayment made pursuant to Section 2.11
(Illegality). For purposes of any IRR calculation for any prepayment fee in the case of a partial prepayment of the BlaO Loan:
(x) all amounts of Additional Interest and fees previously paid to BlaO hereunder shall be deemed to have been allocated to the principal
amount prepaid and all previous installments of principal prepaid or repaid pro rata, on the basis of the percentage of the aggregate
principal amount of the BlaO Loan represented by the relevant prepayment and all previous installments of principal prepaid or repaid;
and (y) the amount prepaid shall be deemed to be comprised of the earliest Disbursement(s) of the BlaO Loan made hereunder.

 

(ii)
Interest and Costs. On the date of each prepayment of the BlaO Loan (including, for the avoidance of doubt, any prepayment made
pursuant to Section 2.11 (Illegality)), the Borrower shall concurrently pay: (a) all accrued and unpaid interest on, and any Increased
Costs incurred in connection with, the BlaO Loan; (b) any Costs then due pursuant to Section 2.12.4 (Other Costs); and (c) any
other Obligations then due and payable.

 

Section
2.5 Application of Prepayments.

 

Amounts
of principal prepaid under Section 2.4 (Voluntary and Mandatory Prepayments) shall be applied by BlaO to the outstanding installments
of principal of the BlaO Loan in inverse order of maturity.

 

Section
2.6 Currency and Place of Payment.

 

2.6.1
Payments of all Obligations shall be made in Dollars, in immediately available funds, to BlaO at:

 

 Intermediary
Bank Name:                                                                                                

 

 Intermediary
Bank SWIFT:                        

 

 Account
Number (IBAN):                              

 

 Beneficiary
Bank Name:                                                            

 

 Beneficiary
Bank SWIFT:                                

 

 Beneficiary
Name:                                                                         

 

 Beneficiary
Account Number:                                                         

 

    - 5 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

or
to such other account as BlaO may instruct (in either case, the “Receipt Account”) by no later than 11:00 a.m. New
York City time, or at such other bank or banks, in such place or places, as BlaO may designate. BlaO may deem any payment received after
that time to have been made on the next Business Day.

 

2.6.2
The payment obligations of the Borrower under this Agreement shall be discharged only to the extent that (and as of the date when) Dollars
are received in the Receipt Account, notwithstanding the tender or payment (including by way of recovery under a judgment) of any amount
in any currency other than Dollars. Accordingly, the Borrower shall pay such additional amount as is necessary to enable BlaO to receive,
after conversion to Dollars, and transfer to the Receipt Account, the full amount due to BlaO under this Agreement. Notwithstanding the
foregoing and Section 2.6.1, BlaO may require the Borrower to pay (or to reimburse BlaO) in any currency other than Dollars for (i) any
Taxes or other amounts payable under Section 2.9 (Taxes) and (ii) any fees or Costs payable under Section 2.12 (Payment of
Fees, Costs and Expenses), in each case to the extent such amounts are payable in such other currency.

 

Section
2.7 Allocation of Partial Payments.

 

If BlaO at
any time receives less than the full amount then due in respect of the Obligations, such amount shall be allocated in the following order,
any: (i) Costs; (ii) fees; (iii) default interest; (iv) ordinary interest;

(v)
Additional Interest; and (vi) principal of the BlaO Loan.

 

Section
2.8 Default Interest.

 

Without
limiting the remedies available to BlaO under this Agreement or otherwise and in addition to any amounts owing pursuant to Section 2.13
(BlaO Loan Interest), if the Borrower fails to pay any Obligation (including interest payable pursuant to this Section 2.8) when
due (whether at maturity or upon acceleration), then the Borrower shall pay default interest on the unpaid amount (i) in the case of
overdue principal, at a rate equal to two percent (2.0%) per annum, (ii) in the case of overdue interest or Additional Interest on the
BlaO Loan, at a rate equal to the sum of two percent (2.0%) per annum plus the Interest Rate, and (iii) for all other overdue
Obligations, at a rate of ten percent (10%) per annum. Interest at such rates shall accrue from the date an Obligation is due until the
date paid and shall be due and payable on the earlier of the date of demand by BlaO and the next Interest Payment Date. Should such default
interest exceed the maximum allowed by Applicable Law, the maximum interest rate allowed by Applicable Law shall apply.

 

Section
2.9 Taxes.

 

2.9.1
The Borrower shall timely pay or cause to be paid (i) all Taxes and other liabilities of whatsoever nature arising in connection
with the payment of any Obligation that are imposed by any Authority of the Borrower’s Country or of any other jurisdiction
from or through which any such payment is made (other than any Taxes on net income) (all such Taxes and other liabilities,
collectively, “Transaction Taxes”) and (ii) all stamp, recording, documentary or similar taxes and all other
charges or levies payable on or in connection with the execution, delivery, registration, consularization, translation, notarization
or enforcement of this Agreement or any other Financing Document (collectively, “Other Taxes”).

 

2.9.2
All payments by the Borrower under this Agreement or under any other Financing Document shall be made free and clear of, and without
deduction or withholding for, any Transaction Taxes or Other Taxes. If the Borrower is required by Applicable Law or otherwise to deduct
or withhold any Transaction Taxes from any such payment, then (i) the amount payable by the Borrower shall be increased as necessary
so that, after making any such required deductions (including deductions applicable to additional amounts payable under this Section
2.9), BlaO receives the full amount it would have received had no such deduction or withholding been required, and (ii) the Borrower
shall make such deduction or withholding and shall pay the full amount deducted or withheld to the relevant Authority in accordance with
Applicable Law.

 

    - 6 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Section
2.10 Suspension of Disbursements; Cancellation of BlaO Loan Commitment.

 

2.10.1
If (i) any Mandatory Prepayment Event has occurred or any Event of Default has occurred and is continuing, (ii) the Borrower’s
Country ceases to be an IDB Invest Member, or (iii) the maximum aggregate number of Disbursements permitted pursuant to Section 2.2.2
(Disbursement Procedure) has been achieved, then, by notice to the Borrower, BlaO may cancel all or any portion of the undisbursed
amount of the BlaO Loan Commitment or suspend the Borrower’s right to request further Disbursements (for such period and on such
conditions as BlaO determines).

 

2.10.2
If the circumstance described in Section 2.11 (Illegality) arises, the BlaO Loan Commitment shall be cancelled as set forth in
such Section; provided, that the amount of the affected BlaO Loan Commitment to be cancelled shall be determined by BlaO. If any
amount of the BlaO Loan Commitment is not disbursed as of the Commitment Termination Date, such amount shall be automatically cancelled.

 

2.10.3
Upon cancellation of the BlaO Loan Commitment pursuant to Sections 2.10.1 or Section 2.10.2, the Borrower shall pay to BlaO, no later
than (i) five (5) Business Days after the occurrence of such cancellation if the cancellation is in full or (ii) the next Interest Payment
Date if such cancellation is a partial cancellation, all fees, Costs and other Obligations (other than outstanding principal of, and
interest and Additional Interest not then due on, the BlaO Loan) accrued through the date of full payment of all such amounts, whether
or not such amounts were otherwise due and payable.

 

2.10.4
The Borrower may, by notice to BlaO and upon payment of all fees, Costs and any other Obligations (other than outstanding principal of,
and interest and Additional Interest not then due on, the BlaO Loan) accrued through such date, irrevocably request BlaO to cancel all
or any portion of the undisbursed amount of the BlaO Loan Commitment (excluding the Interest Reserve Amount during the Interest Reserve
Period) in the amount and on the date specified in such notice; provided, that such date is at least five (5) Business Days (i)
after the date of the notice or (ii) prior to the next succeeding Interest Payment Date; and provided further, that such payment
is made by the Borrower (a) fifteen (15) Business Days after the date of the notice or (b) on the next succeeding Interest Payment Date,
as applicable. BlaO shall, upon receipt of such notice and payment, by notice to the Borrower, cancel such requested portion of the BlaO
Loan Commitment effective as of the date specified in the Borrower’s notice; provided, that the obligation of BlaO to cancel
such requested portion of the BlaO Loan Commitment shall be subject to the condition that Borrower provide evidence satisfactory to BlaO
that the Borrower is making a simultaneous request to make a pro rata cancellation of the commitment for the IDB Invest Loan in
accordance with the terms of the IDB Invest Loan Agreement.

 

2.10.5
The Commitment Fee shall continue to accrue and be payable during any suspension of the Borrower’s right to request Disbursements
pursuant to this Section 2.10 (unless such suspension is a result of the circumstance described in clause (ii) of Section 2.10.1) but,
as of the effective date of any cancellation of the BlaO Loan Commitment, shall cease to accrue with respect to the amount cancelled.

 

2.10.6
Any cancelled portion of the BlaO Loan Commitment shall not be reinstated or disbursed.

 

Section
2.11 Illegality.

 

If
any Change in Law makes it unlawful for BlaO to fund or maintain the BlaO Loan or any portion thereof, the Borrower’s right to
request a Disbursement of the undisbursed portion of the BlaO Loan Commitment affected by the Change in Law shall terminate, and the
Borrower shall, within five (5) Business Days of receipt of notice thereof from BlaO (together with any default interest, losses or any
other additional costs incurred by BlaO until such prepayment is made in full), prepay in full the BlaO Loan, including all interest
and costs provided in Section 2.4.3(ii) (Interest and Costs). No prepayment fee shall be payable in respect of any prepayment
pursuant to this Section 2.11 as well as any accrued but unpaid Additional Interest.

 

    - 7 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

  

Section
2.12 Payment of Fees, Costs and Expenses.

 

2.12.1
Fees. The Borrower shall pay to BlaO:

 

(i)
a commitment fee (the “Commitment Fee”) equal to two and one half percent (2.5%) per annum of the undisbursed and
uncancelled portion of the BlaO Loan Commitment (excluding the Interest Reserve Amount), which shall:

 

		(a)	begin to
                                            accrue daily, in respect of the BlaO Loan Commitment on the earlier of (1) ninety (90) days
                                            after the Effective Date and (2) the first Disbursement date;

 

		(b)	be
                                            calculated on the basis of a three hundred and sixty (360)-day year for the actual number
                                            of days elapsed; and

 

		(c)	be
                                            payable in arrears on the Interest Payment Dates in each year, except that the first such
                                            payment shall be due on the first Interest Payment Date occurring after the date on which
                                            the Commitment Fee begins to accrue;

 

provided,
that, if any Disbursement is made fewer than ten (10) Business Days before an Interest Payment Date, then such Disbursement shall
be disregarded for the purposes of calculating the Commitment Fee due on such Interest Payment Date and any excess Commitment Fee paid
by the Borrower on such Interest Payment Date shall be credited to the Borrower on the next Interest Payment Date;

 

(ii)
on the second (2nd) anniversary of the Effective Date, a one-time payment-in-kind fee equal to two percent (2.0%) per annum of the principal
amount of the BlaO Loan outstanding as of such date (the “PIK Fee”); provided, that the PIK Fee shall not be
payable if, after the first Disbursement Date hereunder and prior to the second (2nd) anniversary of the Effective Date, the Borrower
has received cash proceeds of at least fifty million Dollars ($50,000,000) as a result of a bona fide equity financing transaction or
a series of such transactions with the principal purpose of raising capital pursuant to the issuance and sale of the Borrower’s
Share Capital; and

 

(iii)
in accordance with the Fee Letters of BlaO: (a) a front end fee calculated based on the aggregate amount of the BlaO Loan Commitment;
(b) a waiver and amendment fee; (c) an annual supervision fee; and (d) such other fees, to be agreed upon, if applicable, between BlaO
and the Borrower after the Effective Date, in each case as agreed in writing by BlaO and the Borrower.

 

2.12.2
Expenses. The Borrower shall pay to BlaO, or as BlaO may direct the out-of-pocket expenses (including travel and subsistence expenses,
if applicable) of BlaO and all fees and expenses of BlaO’s legal counsels incurred in connection with:

 

(i)
the preparation, review, negotiation, execution, implementation and, where appropriate, translation, registration and notarization of
the Financing Documents and any other related documents;

 

(ii)
the registration (where applicable) and the delivery of the evidence of indebtedness relating to the BlaO Loan and the Disbursements;

 

    - 8 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(iii)
BlaO’s efforts to preserve, enforce or protect its rights under any Financing Document or upon the exercise of its rights or powers
arising out of the occurrence of any Default, including any related legal and other professional consultants’ fees and expenses
on a full indemnity basis;

 

(iv)
the giving of any legal opinions BlaO requires under this Agreement and any other Financing Document;

 

(v)
any amendment of, supplement or modification to, or waiver under, any Financing Document;

 

(vi)
the occurrence of any Default or Mandatory Prepayment Event; and

 

(vii)
the release of any Security following repayment in full of the BlaO Loan.

 

2.12.3
Increased Costs. On each Interest Payment Date the Borrower shall pay, in addition to any other amounts then due, the amount that
BlaO from time to time notifies to the Borrower as being the Increased Costs accrued and unpaid prior to such Interest Payment Date.

 

2.12.4
Other Costs

 

(i)
The Borrower shall pay to BlaO the amount of any Costs notified by BlaO to the Borrower as incurred by BlaO pursuant to any
Financing Document, including in connection with the cancellation of all or any portion of the BlaO Loan Commitment as provided in
Section 2.10.1 (Suspension of Disbursements; Cancellation of BlaO Loan Commitment), any Disbursement Request delivered
hereunder (regardless of whether the disbursement is finally made or not), or as a result of the Borrower: (a) failing to (1) pay
any Obligation on the due date thereof, (2) borrow in accordance with any Disbursement Request, or (3) make any prepayment pursuant
to Section 2.4.1 (Voluntary Prepayments) in accordance with a notice of prepayment or when due pursuant to Section 2.4.2
(Mandatory Prepayments); or (b) repaying any amount of the BlaO Loan on a date other than an Interest Payment Date (including
as a result of an Event of Default). Payment of amounts due under this Section 2.12.4 shall be made by the Borrower within five (5)
Business Days of receipt of notice thereof (together with any default interest, losses or any other additional costs incurred by
BlaO during such five (5) Business Day period).

 

(ii)
If the Borrower repays any amount of the BlaO Loan on a date other than an Interest Payment Date, then the Costs incurred by BlaO shall
include, and the Borrower shall pay to BlaO, in addition to any other amounts payable by the Borrower under clause (i) of this Section
2.12.4, the amount determined by BlaO as the difference, if any, between (a) the amount of interest that would have accrued on the principal
amount of the BlaO Loan had such repayment not occurred at the Interest Rate then applicable to such Loan for the remainder of the Interest
Period during which the relevant repayment is made, and (b) the amount of interest that BlaO would earn on such repaid principal amount
for the remainder of such Interest Period if such principal amount were invested for such remaining period at the interest rate that
would be bid to BlaO from prime banks in the New York interbank market at the time such repayment occurs.

 

    - 9 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Part
2: Interest Rate Terms and Conditions Section

 

2.13
BlaO Loan Interest.

 

2.13.1
General Provisions.

 

(i)
The Borrower shall pay interest on the outstanding principal amount of the BlaO Loan in accordance with this Section 2.13.

 

(ii)
Interest on the BlaO Loan shall accrue daily for each Interest Period from the first (1st) day of such Interest Period to, the last day
of such Interest Period, computed on the basis of the actual number of days elapsed in such Interest Period in a year of three hundred
and sixty (360) days and shall be payable in arrears on the Interest Payment Date falling on such last day; provided, that the
first (1st) payment of interest on any Disbursement made fewer than ten (10) Business Days before an Interest Payment Date shall be made
on the second (2nd) Interest Payment Date following the date of that Disbursement.

 

2.13.2
Interest Rate. The following terms shall apply the BlaO Loan:

 

(i)
During each Interest Period, the BlaO Loan shall bear interest at the Interest Rate for that Interest Period.

 

(ii)
The variable interest rate applicable to each Disbursement of the BlaO Loan for each Interest Period shall be the sum of (a) Applicable
Term SOFR on the Interest Rate Determination Date for that Interest Period, plus (b) the Applicable Spread.

 

(iii)
On each Interest Rate Determination Date, BlaO shall determine the Interest Rate applicable to the corresponding Interest Period and
BlaO shall promptly notify the Borrower of such rate.

 

(iv)
Notwithstanding anything to the contrary in this Agreement, on each Interest Rate Determination Date on which any amount of the IDB Invest
Loan remains outstanding, BlaO shall use, for the Interest Rate applicable to each Disbursement of the BlaO Loan, the variable interest
rate calculated by IDB Invest for the corresponding disbursements and Interest Periods of the IDB Invest Loan under the IDB Invest Loan
Agreement, unless such calculation involves manifest error.

 

Section
2.14 Additional Interest.

 

(i)
As additional compensation to BlaO for making the BlaO Loan available to the Borrower, the Borrower shall make payments to BlaO in an
aggregate amount equal to three and twenty-seven one hundredths percent (3.27%) of the Adjusted EBITDA for each Financial Year or portion
thereof (the “Additional Interest”), as set forth in this Section 2.14.

 

(ii)
The Additional Interest payments shall be calculated by BlaO as follows:

 

		(a)	for
                                            each Additional Interest Calculation Period ending on June 30th, the amount of Additional
                                            Interest payable shall be calculated by BlaO on the basis of the Adjusted EBITDA for the
                                            six (6)-month period ending on such Financial Quarter Date on the basis of the unaudited
                                            quarterly Financial Statements delivered to BlaO for the relevant Financial Quarters under
                                            Section 5.3.2 (Unaudited Quarterly Financial Statements); and

 

		(b)	for
                                            each Additional Interest Calculation Period ending on December 31st, the amount of Additional
                                            Interest payable shall be calculated by BlaO on the basis of the Adjusted EBITDA for the
                                            Financial Year ending on such date on the basis of the audited annual Financial Statements
                                            delivered to BlaO for such Financial Year under Section 5.3.1(ii) (Audited Annual Financial
                                            Statements);

 

    - 10 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

provided,
that if the Borrower fails to deliver such quarterly or annual Financial Statements when and as required by Sections 5.3.1(ii) and 5.3.2,
BlaO may calculate the Additional Interest based on such information as is available to it, but the Borrower and BlaO agree that the
amount of such payment shall thereafter be subject to adjustment if the final calculation of Additional Interest based on the annual
Financial Statements is different.

 

(iii)
The amount of Additional Interest shall be payable as follows:

 

		(a)	for
                                            the Additional Interest Calculation Period ending on June 30, the Borrower shall pay to BlaO
                                            an amount equal to the Additional Interest calculated under Section 2.14(ii)(a) for such
                                            Additional Interest Calculation Period on the following October 15; and

 

		(b)	for
                                            the Additional Interest Calculation Period ending on December 31, the Borrower shall pay
                                            to BlaO an amount equal to the Additional Interest for such Additional Interest Calculation
                                            Period on April 15 of the succeeding Financial Year; provided, that from such payment
                                            there shall be subtracted the Additional Interest amount paid by the Borrower pursuant to
                                            paragraph (a) above in respect of the first half of the relevant Financial Year;

 

provided,
however, that in each case, if the Additional Interest payment calculated by BlaO for any Additional Interest Calculation Period
is negative, the Additional Interest payment shall be equal to zero.

 

(iv)
Notwithstanding anything to the contrary above in this Section 2.14, Additional Interest shall accrue at the conclusion of each Additional
Interest Calculation Period during which any amount of principal of the BlaO Loan remains outstanding (whether or not such principal
amount was outstanding for all or only a portion of the relevant Additional Interest Calculation Period).

 

(v)
Subject to the proviso of clause (ii) and the preceding clause (iv), all calculations of the Additional Interest made by BlaO from time
to time shall be binding absent manifest error.

 

Section
2.15 Market Disruption.

 

2.15.1
If BlaO determines that for any Interest Period, Applicable Term SOFR (i) will not adequately reflect the cost of making, funding or
maintaining the BlaO Loan or (ii) subject to Section 2.16 (Benchmark Replacement Setting), cannot be determined by BlaO pursuant
to the definition thereof (each of the foregoing, a “Market Disruption Event”), then the Market Disruption Base Rate,
as notified by BlaO to the Borrower, shall apply to the BlaO Loan for each Interest Period in place of Applicable Term SOFR. Any Market
Disruption Base Rate applied pursuant to this Section 2.15.1 shall cease to be used in place of Applicable Term SOFR (a) for any Interest
Period that begins after BlaO notifies the Borrower that the Market Disruption Event no longer exists or (b) if an agreement is reached
between BlaO and the Borrower during the Rate Setting Period, as described in Section 2.15.2(ii).

 

2.15.2
(i) Upon the occurrence of a Market Disruption Event where Applicable Term SOFR will not adequately reflect the cost of making, funding
or maintaining the BlaO Loan, BlaO may elect to apply Applicable Term SOFR to determine the weighted average cost of funds of BlaO when
calculating the interest rate for the BlaO Loan.

 

    - 11 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(ii)
Notwithstanding the foregoing, upon the occurrence of a Market Disruption Event, at the Borrower’s written request (received by
BlaO within five (5) Business Days of the Borrower having been notified by BlaO of such Market Disruption Event), (a) BlaO and the Borrower
shall enter into good faith negotiations for a period of not more than thirty (30) days (the “Rate Setting Period”)
to determine a substitute base rate of interest applicable to the BlaO Loan; (b) any alternative rate agreed to by BlaO and the Borrower
during the Rate Setting Period shall apply retroactively from the first day of the affected Interest Period; and (c) if no agreement
is reached between BlaO and the Borrower during the Rate Setting Period, the Borrower may prepay the relevant portion of the BlaO Loan
no later than five (5) Business Days following the expiration of the Rate Setting Period. Any such prepayment shall be made together
with all interest and costs provided in Section 2.4.3(ii) (Prepayment Fees and Costs).

 

2.15.3
Notwithstanding anything to the contrary in this Agreement, if (i) a Market Disruption Event occurs at a time when any amount of the
IDB Invest Loan remains outstanding and (ii) IDB Invest determines that a market disruption event has also occurred in respect of the
IDB Invest Loan, then BlaO shall use the Market Disruption Base Rate calculated by IDB Invest under the IDB Invest Loan Agreement for
the corresponding Interest Period of the IDB Invest Loan, unless such calculation involves manifest error.

 

Section
2.16 Benchmark Replacement Setting.

 

2.16.1
Benchmark Replacement. Notwithstanding anything to the contrary herein or in any other Financing Document, upon the occurrence
of a Benchmark Transition Event, BlaO may amend this Agreement and any other Financing Document to replace the then-current Benchmark
with a Benchmark Replacement. Any such amendment will become effective on the fifth (5th) Business Day in New York after BlaO has sent
a notice of such proposed amendment to the Borrower or such later date as BlaO may specify in such notice, without any further action
or consent of the Borrower.

 

2.16.2
Benchmark Replacement Conforming Changes. In connection with the use, administration, adoption or implementation of a Benchmark
Replacement, BlaO will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything
to the contrary herein or in any other Financing Document, any amendments implementing such Benchmark Replacement Conforming Changes
will become effective upon notice to, but without any further action or consent of the Borrower.

 

2.16.3
Notices; Standards for Decisions and Determinations. BlaO will promptly notify the Borrower of (i) the implementation of any Benchmark
Replacement and (ii) the effectiveness of any Benchmark Replacement Conforming Changes. Any determination, decision or election that
may be made by BlaO pursuant to this Section 2.16, including any determination with respect to a tenor, rate or adjustment or the occurrence
or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and
binding absent manifest error and may be made in BlaO’s sole discretion. In connection with the implementation of any Benchmark
Replacement and at the request of BlaO, the Borrower shall promptly provide an amendment to or replacement of any affected Note.

 

2.16.4
Determinations while the IDB Invest Loan is Outstanding. Notwithstanding anything to the contrary in this Agreement, if a Benchmark
Transition Event occurs while any amount of the IDB Invest Loan remains outstanding, for the purposes of this Section 2.16, BlaO shall
use the (i) Benchmark Replacement, (ii) the Benchmark Replacement Adjustment, and (iii) the Benchmark Replacement Conforming Changes
determined by IDB Invest under the IDB Invest Loan Agreement, unless such determination involves manifest error.

 

    - 12 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Part
3: Promissory Notes

 

Section
2.17 Notes.

 

2.17.1
Initial Notes. To further evidence its obligation to repay the BlaO Loan, and to pay accrued interest, the Borrower shall issue
and deliver to BlaO, on or prior to the first Disbursement Date (i) a partially completed promissory note with the principal amount blank
and (ii) an instruction letter, each in form and substance acceptable to BlaO (collectively, the “Notes”). At BlaO’s
request from time to time, the Borrower shall promptly execute and deliver one or more new Notes satisfactory to BlaO to substitute for
one or more Notes previously delivered hereunder. Upon the receipt of such executed replacement Notes, BlaO shall promptly return to
the Borrower the original Notes so replaced or an affidavit of loss or destruction in customary form. The issuance, execution and delivery
of any Note pursuant to this Agreement shall not be construed as a novation hereunder or under any other agreement between BlaO and the
Borrower and shall not affect the obligations or rights of the Borrower hereunder, and the rights and claims of BlaO under any Note shall
not replace or supersede its rights and claims hereunder.

 

2.17.2
Replacement Notes. At the time of the last Disbursement of the BlaO Loan, or upon BlaO’s request thereafter, the Borrower
shall deliver to BlaO a Note in the total amount of all Disbursements of the BlaO Loan (including the amount of such last Disbursement)
to be due and payable on the Loan Final Maturity Date; provided, that if the Borrower has made any payments of principal pursuant
to Section 2.3 (Repayment), then the Note shall be for the total amount remaining due under the BlaO Loan after such payment(s)
of principal have been made, as calculated by BlaO and notified to the Borrower.

 

ARTICLE
3

 

Representations
and Warranties

 

Section 3.1 Representations and Warranties.

 

The Borrower
represents and warrants in respect of itself and each of the Guarantors that:

 

3.1.1
Organization; Power; Due Authorization. It is, duly organized and validly existing and (if applicable) in good standing under
the Applicable Law of its jurisdiction of organization and is authorized to do business in such jurisdiction and each other jurisdiction
where the character of its Property or the nature of its activities makes such authorization necessary. It has all requisite corporate
or other organizational power and authority: (i) to own its Property, (ii) to conduct its business as currently conducted, and (iii)
to enter into, and to comply with its obligations under, each Financing Document to which it is or will be a party.

 

3.1.2
Enforceability. This Agreement and the other Financing Document to which it is a party are, or when duly executed and delivered,
will be (i) duly authorized and executed by it and constitute its valid and legally binding obligation, enforceable in accordance with
its terms and (ii) in proper legal form for the enforcement thereof under the Applicable Law of its jurisdiction of organization and,
if this Agreement were stated to be governed by such law, it would constitute its legal, valid, and binding obligation under such law.

 

3.1.3
No Violation. Neither its execution and delivery of any Financing Document to which it is a party nor its compliance with the
terms thereof will: (i) contravene any Applicable Law or Relevant Authorization; (ii) result in any breach of, or constitute a default
or require any consent under, any agreement or other arrangement to which it is a party, by which it is bound or to which it may be subject;

(iii)
result in the creation or imposition of (or an obligation to create or impose) any Lien upon any of its Property; (iv) violate the terms
of its organizational documents.

 

    - 13 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

3.1.4
Relevant Authorizations. Except as disclosed in Schedule 3.1.4: (i) it has all Relevant Authorizations to conduct its business
and to enter into, and to comply with its obligations under, each Financing Document to which it is or will be a party; (ii) each such
Relevant Authorization has been validly issued and obtained and is in full force and effect; (iii) no Relevant Authorization is the subject
of an appeal or judicial or other review by any Authority; (iv) it is in compliance with each Relevant Authorization; and (v) it has
no reason to believe that any Relevant Authorization that requires renewal will not be renewed as and when required under Applicable
Law without the imposition of additional restrictions or conditions or that any Relevant Authorization will be withdrawn, suspended,
cancelled, varied, surrendered or revoked.

 

3.1.5
Compliance with Applicable Laws. It is in compliance with Applicable Law.

 

3.1.6
No Default. No Default has occurred and is continuing.

 

3.1.7
Litigation.

 

(i)
No Action is pending (or, to its knowledge, threatened) against it or any of its Affiliates that has had or could reasonably be expected,
by itself or together with any other Action, to have a Material Adverse Effect; and

 

(ii)
no judgment, order or award has been issued that has had, or could reasonably be expected by itself or together with any other judgment,
order or award or pending Action against it or any of its Affiliates to have, a Material Adverse Effect.

 

3.1.8
Financial Statements.

 

(i)
The unaudited Financial Statements for the annual period ending on December 31, 2021, the unaudited Financial Statements for the Financial
Quarter ending on December 31, 2021, and the audited Financial Statements for the annual period ending on December 31, 2020 delivered
to BlaO were prepared from and are in accordance with its books and records and give a true and fair view of its financial position,
including disclosure of all of its liabilities (contingent or otherwise) as of the date thereof and the results of its operations and
cash flow for the period covered thereby, all in conformity with the Accounting Principles.

 

(ii)
It has not undertaken or agreed to undertake any material obligation not shown in its Financial Statements most recently delivered to
BlaO other than its obligations under the Financing Document or, if applicable, its obligations under the SPAC Transaction documents.

 

3.1.9
No Material Adverse Effect. Since December 31, 2020, no condition has existed, or event has occurred that has had or could reasonably
be expected to have a Material Adverse Effect.

 

3.1.10
Ownership of Property; Liens; Intellectual Property. It has good, legal, and valid title to (or a valid leasehold interest in)
all its Property (including all Intellectual Property required in connection with its business), and with respect to the Secured Property,
free of all Liens other than Permitted Liens.

 

3.1.11
Environmental and Social Compliance. Each representation made in Section 2 (E&S Representations and Warranties) of
Annex 2 (Environmental and Social Provisions) is true and correct.

 

3.1.12
Absence of Prohibited Practices; Sanctions Lists. Neither it nor any of its Affiliates nor any Person acting on its or their behalf
(i) has committed or engaged in any Prohibited Practice in connection with any Financing Document or any transaction contemplated by
the Financing Documents or (ii) is included on any Internationally Recognized Sanctions Lists or on the IDB Group List of Sanctioned
Firms and Individuals.

 

    - 14 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

3.1.13
Legal Form; Enforceability. Subject to the immediately following sentence, this Agreement and the other Financing Documents to
which it is a party are, or when duly executed and delivered will be, in proper legal form for the enforcement thereof under the Applicable
Law of its jurisdiction of organization. Each Note when delivered constitutes a título ejecutivo under the Applicable Laws
of the Borrower’s Country. All formalities required in its jurisdiction of organization for the validity and enforceability of
this Agreement and the other Financing Documents (including any necessary translation, notarization, consularization, apostille or legalization,
registration, recording or filing with any court, registry or other Authority in its jurisdiction of organization) have been or will
be accomplished prior to the first Disbursement Date other than a translation of this Agreement into Spanish, prepared by an official
translator.

 

3.1.14
Ranking of Obligations. Its obligations under the Financing Documents to which it is a party to pay the principal of and interest
on the BlaO Loan and any and all other amounts due thereunder constitute its senior, direct and unconditional unsubordinated obligations
and will at all times rank at least equal in right of payment with all of its other present and future unsubordinated indebtedness and
other obligations of the Borrower.

 

3.1.15
Availability and Transfer of Foreign Currency. Other than the registration of the BlaO Loan with the Colombian Central Bank (Banco
de la República) which will be satisfied by (a) filing Form No. 6 (Información de Endeudamiento Externo otorgado
a Residentes) prior to, or simultaneously with, the first Disbursement and (b) Form No. 3 (Declaración de Cambio) prior
to, or simultaneously with, each Disbursement, each with an authorized foreign exchange intermediary, no foreign exchange control approvals
or other Authorizations are required to ensure the availability of Dollars to enable it to perform all of its obligations under the Financing
Documents to which it is a party. No other restriction or requirement limits the availability to, or transfer of foreign exchange by,
it to make any payments required under any Financing Document to which it is a party.

 

3.1.16
Absence of Insolvency Event. No Insolvency Event has occurred and is continuing or, to its knowledge, has been threatened against
it, and it has not taken any action that will result in an Insolvency Event.

 

3.1.17
Choice of Law; Consent to Jurisdiction. Under the Applicable Law of its jurisdiction of organization, the choice of the law of
New York to govern this Agreement and the other Financing Documents which are subject to New York law is valid and binding. Its consent
to the jurisdiction of the courts provided in Section 7.10.2 (Applicable Law and Jurisdiction) is valid, binding and irrevocable,
and service of process effected in the manner provided in Sections 7.10.4 and 7.10.6 will be effective to confer personal jurisdiction
over it in such courts.

 

3.1.18
No Immunity. Neither it nor any of its Property has any immunity from execution or set-off with respect to its assets, or suit
with respect to its obligations under this Agreement, the Notes or any other Financing Document.

 

3.1.19
Provision of Information, Etc. All written information provided by it to BlaO was, on the date provided, and continues to be,
true and accurate in all material respects and not misleading in any material respect nor is any information omitted from such information
that makes the information provided misleading in any material respect (except to the extent that it has provided to BlaO written updates
or amendments to such previously furnished information reflecting changes in circumstance subsequent to the provision of such information).

 

    - 15 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

3.1.20 Taxes.

 

(i)
(a) All of its Tax Returns that are required by Applicable Law to be filed have been duly filed; (b) all Taxes due and payable by it,
or upon its Property, income or assets, which are due and payable or required to be deducted or withheld, have been paid or deducted
or withheld and properly paid to the appropriate Authority, except for Taxes being diligently contested in god faith through the appropriate
proceedings, with respect to which reserves have been established.

 

(ii)
Except as otherwise disclosed in the Financial Statements referred to in Section 3.1.8 (Financial Statements), it has not received
notice of (a) any pending audits, examinations, investigations, proceedings or claims with respect to any Taxes or (b) any Lien with
respect to Taxes that has been filed against any of its Property, nor to its knowledge, in either case, has any such action been threatened.

 

3.1.21
Affiliate Transactions. As of the Effective Date, there have been no Affiliate Transactions except those carried out in the ordinary
course of business and at arm’s-length.

 

3.1.22
Status of Security.

 

(i)
The Security Documents create, or when executed and duly registered will create, valid and enforceable first priority Liens (or other
interests or rights of the kind purported to be created thereby) over all of the Secured Property.

 

(ii)
It has not received any notice of any adverse claim by any Person in respect of its ownership of, or entitlement to, the Secured Property.

 

(iii)
The Secured Property is not, and will not at any time be, subject to any Lien other than pursuant to the Security Documents.

 

3.1.23
Borrower’s Share Capital. The Share Capital of the Borrower consists solely of the number of shares and classes of capital
stock set forth in Schedule 6 (Borrower’s Share Capital), all of which are held beneficially and of record by the
Persons listed in Schedule 6 (Borrower’s Share Capital). No other Person holds any Share Capital of, or any Equity
Rights in respect of, the Borrower.

 

3.1.24
Subsidiaries.

 

(i)
Merqueo Brazil, Merqueo International, and Merqueo Mexico are the only direct or indirect Subsidiaries of the Borrower as of the Effective
Date and the Borrower (and, if applicable, Merqueo International) holds the following (a) number of fully paid and non-assessable shares
of each of its Subsidiaries and (b) percentage ownership in each class of capital stock of each of its Subsidiaries:

 

		(1)	Merqueo
                                            Brazil.

 

	Shareholder	Type
    of Share	Number
    of Shares	Participation
	The
    Borrower	Common	77,516,554	99%
	Merqueo
    International	Common	9,900	1%
	Total	 	77,526,454	100%

 

		(2)	Merqueo
                                            International.

 

	Shareholder	Type
    of Share	Number
    of Shares	Participation
	The
    Borrower	Common	1,000,000	100%

 

    - 16 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

		(3)	Merqueo
                                            Mexico.

 

	Shareholder	Type
    of Share	Number
    of Shares	Participation
	The
    Borrower	Common	246,331,597	98.47%
	Merqueo
    International	Common	3,839,117	1.53%
	Total	 	250,170,714	100%

 

(ii)
The Borrower (and, if applicable, Merqueo International) has good, legal, and valid title to all of its Subsidiaries’ shares, free
of all Liens other than Permitted Liens.

 

(iii)
Other than its direct or indirect ownership of Merqueo Brazil, Merqueo International, and Merqueo Mexico and any Subsidiaries formed
after the Effective Date in accordance with Section 5.2.14 (Negative Covenants), neither the Borrower nor any of its Subsidiaries
holds, directly or indirectly, any Share Capital or Equity Rights of any other Person.

 

3.1.25
No Omissions. No representation or warranty in this Article 3 (Representations and Warranties) omits any matter the omission
of which makes such representation or warranty misleading.

 

Section
3.2 Acknowledgment and Warranty.

 

The
Borrower acknowledges that it makes the representations and warranties contained in Section 3.1 (Representations and Warranties)
with the intention of inducing BlaO to enter into this Agreement and the other Financing Documents and that BlaO has entered into this
Agreement and the other Financing Documents on the basis of, and in full reliance upon, each such representations and warranties.

 

ARTICLE
4

 

Conditions
Precedent to Disbursement 

 

Section
4.1 Conditions Precedent to First Disbursement.

 

The
first Disbursement is subject to the fulfillment in form and substance, and in a manner, satisfactory to BlaO, not later than three (3)
Business Days prior to the applicable Disbursement Date of the following conditions; provided, that any condition that is specified
to be required to be met on the Disbursement Date shall be satisfied on or before the Disbursement Date as a condition to the making
of the Disbursement to be made on such date:

 

4.1.1
Organizational Documents; Corporate Resolutions; Incumbency. BlaO has received a certificate from the Borrower substantially in
the form of Exhibit 2 (Form of Borrower’s Certificate Regarding Organizational Documents/Corporate Resolutions) signed
by an Authorized Representative of the Borrower and each Guarantor and dated as of the date of the relevant Disbursement Request and
attaching all required documents.

 

4.1.2
Environmental and Social. The conditions in Section 3 (E&S Conditions Precedent to First Disbursement) of Annex
2 (Environmental and Social Provisions) have been satisfied.

 

4.1.3 Legal
Opinions. BlaO has received a legal opinion dated as of the first Disbursement Date and addressed to each Senior Lender from:

 

(i)
the Borrower’s in-house legal counsel, substantially in the form attached as Exhibit 8 (Form of Borrower’s Legal
Opinion);

 

    - 17 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(ii)
Gómez-Pinzón Abogados S.A.S., the Borrower’s Country counsel to the Senior Lenders, in form and substance acceptable
to BlaO;

 

(iii)
Becker, Glynn, Muffly, Chassin & Hosinski LLP, New York counsel to the Senior Lenders, in form and substance acceptable to BlaO;

 

(iv)
Barbosa, Müssnich e Aragão Advogados, Brazil counsel to the Senior Lenders, in form and substance acceptable to BlaO (but
which shall not cover the enforceability of the Guarantee Agreement); and

 

(v)
Mijares Angoitia Cortés y Fuente, S.C., Mexico counsel to the Senior Lenders, in form and substance acceptable to BlaO (but which
shall not cover the enforceability of the Guarantee Agreement).

 

4.1.4
Financial Statements. BlaO has received the Financial Statements referred to in Section 3.1.8(i) (Financial Statements).

 

4.1.5
Financing Documents. Each Financing Document (other than any Financing Document to be entered into by IDB Invest) has been duly
authorized and executed and delivered by all parties thereto and is in full force and effect in accordance with its terms, and all formalities
required in the Borrower’s Country for the validity and enforceability of this Agreement and the other Financing Documents (including
any necessary translation (sworn or otherwise), notarization, consularization, apostille or legalization, registration, recording or
filing with any court, registry or other Authority in the Borrower’s Country) have been or will be accomplished prior to the first
Disbursement Date.

 

4.1.6
IDB Invest Board Approval. The Board of Executive Directors of IDB Invest has approved the IDB Invest Loan.

 

4.1.7
Security. The Security has been duly created and perfected; the Security Documents have been duly executed and, if required, have
been registered in the appropriate public registry, creating valid and enforceable first priority Liens over the Secured Property, and
the Secured Property shall be satisfactory in form and substance to BlaO.

 

4.1.8
Process Agent. BlaO has received (i) a letter substantially in the form of Exhibit 3 (Form of Borrower’s Service
of Process Letter) relating to the appointment by the Borrower and each Guarantor of an agent for service of process acceptable to
BlaO and (ii) in respect of Merqueo Mexico only, a notarial power of attorney for acts of administration to such Process Agent (in form
and substance satisfactory to BlaO), together with evidence of such Process Agent’s unconditional acceptance of such appointment
and power of attorney to act as such until the date that is six (6) months after the Loan Final Maturity Date.

 

4.1.9
Authorization to Auditor. BlaO has received a copy of the authorization to the Auditor, substantially in the form of Exhibit
4 (Form of Authorization to Auditor), signed by an Authorized Representative of the Borrower and countersigned by the Auditor
(to the extent such Auditor is willing to countersign the same, after the Borrower has made commercially reasonable efforts to request
such countersignature).

 

Section
4.2 Conditions Precedent to Second Disbursement.

 

The
second Disbursement is subject to the fulfillment in form and substance, and in a manner, satisfactory to BlaO, not later than three
(3) Business Days prior to the applicable Disbursement Date of the following conditions; provided, that any condition that is specified
to be required to be met on the Disbursement Date shall be satisfied on or before the Disbursement Date as a condition to the making
of the Disbursement to be made on such date:

 

4.2.1
Intercreditor Agreement. BlaO and IDB Invest have entered into the Intercreditor Agreement, which has become unconditional and
fully effective.

 

    - 18 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

4.2.2
IDB Invest Loan Disbursement. Each Financing Document to be entered into by IDB Invest have been duly authorized and executed
and delivered by all parties thereto and is in full force and effect in accordance with its terms, and the Borrower has simultaneously
requested a disbursement of the IDB Invest Loan under the IDB Invest Loan Agreement.

 

4.2.3
Series C+ Investment; Note Conversion. (i) The investment in the Series C+ Preferred Shares of the Borrower under the Subscription
Agreement among the Borrower, IDCV MERQUEO FUEL K/S and the other parties thereto dated as of October 25, 2021 has been consummated in
all material respects in accordance with its terms, with aggregate proceeds received by the Borrower equal to at least thirty-six million
two hundred fifty thousand Dollars ($36,250,000); and (ii) the Borrower does not have any convertible instruments outstanding.

 

4.2.4
Certain Corporate Matters. (i) Merqueo Brazil and Merqueo Mexico have concluded their respective capitalization processes and,
if requested by BlaO, it has received satisfactory evidence thereof; and (ii) the organizational documents of Merqueo Mexico have been
amended, in form and substance satisfactory to BlaO, in order to permit Merqueo Mexico to enter into the Guarantee Agreement and the
IDB Invest Guarantee Agreement.

 

Section
4.3 Conditions Precedent to All Disbursements.

 

All
Disbursements (including, except where otherwise stated, the first and second Disbursement) are subject to the fulfillment in form and
substance, and in a manner, satisfactory to BlaO, not later than three (3) Business Days prior to the applicable Disbursement Date of
the following conditions; provided, that any condition that is specified to be required to be met on the Disbursement Date shall
be satisfied on or before the Disbursement Date:

 

4.3.1
Disbursement Request. BlaO has received a Disbursement Request with respect to such Disbursement in accordance with Section 2.2
(Disbursement Procedure) certifying as to the intended use of proceeds, which shall comply with Section 5.1.1 (Use of Proceeds)
and the satisfaction of all applicable conditions to Disbursement.

 

4.3.2
No Default. No Default exists or will occur as a result of the making of such Disbursement.

 

4.3.3
Representations and Warranties. All representations and warranties made by the Borrower in Article 3 (Representations and Warranties)
are true and correct with reference to the facts and circumstances existing on the date of the applicable Disbursement Request and on
the applicable Disbursement Date, with the same effect as if made on each such date, after giving effect to the proposed Disbursement
to be made on such date; provided, that references to Financial Statements shall be deemed to refer to the most recent Financial
Statements delivered to BlaO as of such date; provided further, that references to the Subsidiaries under Section 3.1.24 (Subsidiaries)
shall be deemed to include any existing Subsidiaries formed after the Effective Date in compliance with Section 5.1.14 (Subsidiaries).

 

4.3.4
Fees and Expenses. The Borrower has paid: (i) all fees due prior to or as of the relevant Disbursement Date pursuant to any Fee
Letter or other Financing Document, and BlaO has been reimbursed for all Costs, (ii) all fees and expenses of BlaO’s legal counsels,
and (iii) any other fees and expenses required by any Financing Document to be reimbursed by the relevant Disbursement Date, or the Borrower
has made arrangements satisfactory to BlaO that such payments will be made.

 

    - 19 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

4.3.5
Subsequent Legal Opinions. If BlaO requests, BlaO has received in form and substance acceptable to BlaO a legal opinion or opinions
from counsel acceptable to BlaO covering such matters as BlaO may reasonably require.

 

4.3.6
Material Adverse Effect. Since the Effective Date, nothing has occurred that has had or could reasonably be expected to have a
Material Adverse Effect.

 

4.3.7
Environmental and Social. All conditions set forth in Section 4 (E&S Conditions Precedent to All Disbursements) of
Annex 2 (Environmental and Social Provisions) have been satisfied.

 

4.3.8
Financial Covenants. The Borrower shall be in compliance with Section 5.1.13 (Financial Covenants) after taking into account
the amount of the Disbursement to be made and any other Debt incurred by the Borrower and any capital contribution made after the date
of the latest Financial Statements provided pursuant to Section 5.3.1 (Audited Annual Financial Statements) or Section 5.3.2 (Unaudited
Quarterly Financial Statements).

 

4.3.9
Notes. On or before the applicable Disbursement Date, the Borrower shall have duly executed and delivered to BlaO a Note in the
amount of the requested Disbursement dated as of such Disbursement Date which, when delivered, shall constitute a título ejecutivo
under the Applicable Laws of the Borrower’s Country.

 

4.3.10
Authorizations. Except as disclosed in Schedule 3.1.4, all Relevant Authorizations are in full force and effect and copies thereof
have been delivered to BlaO if requested.

 

4.3.11
Key Performance Indicators. The Borrower is in compliance with the Key Performance Indicators.

 

4.3.12
Colombian Central Bank Registration. In accordance with Applicable Law, the relevant Disbursement has been registered with the
Colombian Central Bank (Banco de la República) (or evidence that such registration has been initiated on or before the
proposed Disbursement Date has been delivered to BlaO).

 

ARTICLE
5

 

Covenants

 

Section
5.1 Affirmative Covenants.

 

The Borrower
shall, and shall cause each of its Subsidiaries to:

 

5.1.1
Use of Proceeds. Cause the proceeds of the BlaO Loan to be applied exclusively in the Borrower’s Country, Mexico and Brazil,
for (i) the expansion of current operations, whether conducted directly or indirectly through any of the Guarantors, (ii) working capital
needs, (iii) capital expenditures needs, and (iv) in the case of the Interest Reserve Amount, payments of interest on the Loan, all in
accordance with Applicable Law and the terms of this Agreement; provided, that the proceeds of all Disbursements shall not be
used to finance activities listed in the List of Excluded Activities.

 

5.1.2
Existence; Continuing Engagement in Business. Maintain its corporate existence and take all reasonable actions necessary to obtain
and maintain in full force and effect all Relevant Authorizations, all Intellectual Property required in connection with its Business
and all other rights, privileges and franchises necessary or desirable in the normal conduct of its Business.

 

    - 20 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

5.1.3
Conduct of Business; Compliance with Applicable Laws. Conduct its business in accordance with prudent industry practice, the Relevant
Authorizations and all other Applicable Laws.

 

5.1.4
Systems; Books and Records. Maintain an accounting system, a management information system and books of account and other records
adequate to reflect accurately and fairly its financial condition and the results of its operations in conformity with the Accounting
Principles, Applicable Law and prudent industry practice.

 

5.1.5
Access to Premises and Records. Upon BlaO’s request, permit representatives and staff of BlaO to:

 

(i)
visit and inspect any premises where the Borrower’s or any Subsidiary’s business is conducted;

 

(ii)
inspect all facilities, plant and equipment of the Borrower or any Subsidiary and examine and make abstracts and/or reproductions of
their books of account and records, including records pertaining to compliance with Environmental and Social Requirements (as defined
in Annex 2 (Environmental and Social Provisions)) and Prohibited Practices; and

 

(iii)
have access to the Borrower’s and its Subsidiaries’ employees, officers, agents, Auditors, contractors and/or subcontractors.

 

5.1.6
Auditor. Maintain an Acceptable Auditor as its auditor. In the event of any change in the Auditor to another Acceptable Auditor,
the Borrower shall deliver to BlaO no later than five (5) Business Days following the Borrower’s appointment of a new Acceptable
Auditor, a written notification of such appointment.

 

5.1.7
Ranking of Obligations. Take such action as may be necessary to ensure that, at all times, the Obligations are senior, direct
and unconditional unsubordinated obligations of the Borrower that rank at least equal in right of payment with all other present and
future unsubordinated and unsecured indebtedness and other obligations of the Borrower, other than those preferred solely by the Applicable
Laws of the Borrower’s Country relating to bankruptcy, insolvency, liquidation or other similar laws of general application.

 

5.1.8
Environmental and Social Compliance. Comply with Sections 5 (E&S Affirmative Covenants) and 6 (E&S Negative
Covenants) of Annex 2 (Environmental and Social Provisions).

 

5.1.9
Cooperation. If BlaO notifies the Borrower that a misrepresentation may have been made with respect to Section 3.1.12 (Absence
of Prohibited Practices; Sanctions Lists), or a breach under Section 5.2.7 (Prohibited Practices), Section 5.2.8 (List
of Excluded Activities) or Section 5.3.3(ii)(e) (Information - Notices) has occurred, then (i) cooperate in good faith with
BlaO and its representatives in determining whether such misrepresentation or breach has occurred, (ii) respond promptly (and in any
event within five

(5)
days) with reasonable detail to any notice from BlaO relating thereto, and (iii) upon BlaO’s request, furnish documentary support
for such response.

 

5.1.10
Taxes. (i) Pay and discharge all Taxes imposed upon its Property, income or profits and deduct or withhold all Taxes required
to be deducted or withheld and properly pay such Taxes to the appropriate Authority when required under Applicable Law, provided, that
neither the Borrower nor any Subsidiary shall be required to pay any such Tax which is being diligently contested in good faith by appropriate
proceedings with respect to which it has established adequate reserves; and (ii) file all Tax Returns as and when required by Applicable
Law to be filed by it; and (iii) pay any Tax imposed by any Authority of its jurisdiction of organization or operation, if any, in relation
to the execution, delivery, registration, notarization or enforcement of any Financing Document.

 

    - 21 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

5.1.11
Insurance.

 

(i)
Maintain insurance policies with reputable insurers in the ordinary course of business;

 

(ii)
permit BlaO to review copies of any insurance policy of the Borrower or any of its Subsidiaries, if reasonably requested by BlaO;

 

(iii)
promptly notify the relevant insurer of any claim by the Borrower under any policy written by that insurer and diligently pursue that
claim, except for immaterial claims where, in the reasonable judgment of the Borrower or any of its Subsidiaries, the cost to pursue
such claim would exceed the amount of such claim; and

 

(iv)
use any insurance proceeds it receives including from BlaO as loss payee with respect to any Secured Property for the loss of, or damage
to, any material asset, or to compensate any Person that has suffered a loss, solely (i) to replace or repair that asset, (ii) pay such
Person as applicable, or (iii) to prepay the BlaO Loan within five (5) Business Days of receipt thereof.

 

5.1.12
Perfection and Maintenance of Security.

 

(i)
With respect to any Security Document entered into after the Effective Date, file for registration no later than five (5) Business Days,
and register no later than ninety (90) days, in each case after the execution thereof, such Security Document at the relevant public
registry in the Borrower’s Country and provide to BlaO a copy of evidence of such registration within thirty (30) days of receipt
thereof.

 

(ii)
At all times, maintain the Security free and clear of all Liens in accordance with the Security Documents for the sole and exclusive
benefit of the Senior Lenders and, at the request of BlaO, perform all acts and make, execute, deliver and file all documents (including,
if applicable, any financing statements, registration statements, continuation statements or other statements) or instruments required
in order to ensure that the Senior Lenders at all times hold a first priority perfected Lien in all Secured Property pursuant to the
terms of the Security Documents, including, at BlaO’s request, defending, at the Borrower’s expense, the Senior Lenders’
right, title and interest to the Security and the Secured Property.

 

5.1.13
Financial Covenants. Maintain at all times the following ratios (the “Financial Covenants”):

 

(i)
beginning with the second Financial Quarter of the 2023 Financial Year, a Minimum Prospective DSCR of not less than:

 

		(a)	1.20:1
                                            for the second, third, and fourth Financial Quarters of the 2023 Financial Year;

 

		(b)	1.25:1
                                            for each Financial Quarter of the 2024 Financial Year; and

 

		(c)	1.30:1
                                            for each Financial Quarter thereafter;

 

(ii)
beginning with the second Financial Quarter of the 2023 Financial Year a Minimum Historical DSCR of not less than 1.30:1; and

 

    - 22 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(iii)
beginning with the fourth Financial Quarter of the 2024 Financial Year, a Maximum Net Debt to Consolidated EBITDA Ratio of not more than:

 

		(a)	3:1 for
                                            the fourth Financial Quarter of the 2024 Financial Year;

 

		(b)	2.5:1 for
                                            each Financial Quarter of the 2025 Financial Year; and

 

		(c)	2:1 for
                                            each Financial Quarter thereafter.

 

For
any determination date for which Financial Statements are not available, the Borrower shall calculate its compliance with this Section
5.1.13 on such date based on documentation available to it (including financial records, reports and any other documents acceptable to
BlaO), which calculations and documenting basis shall be provided to BlaO upon its request.

 

5.1.14
Beneficial Ownership. Cooperate with and support BlaO’s efforts to obtain beneficial ownership information from upstream
holders of Share Capital of the Borrower.

 

5.1.15
Compliance with Laws against Money Laundering and Combating the Financing of Terrorism. Adopt and comply with internal policies,
procedures, and controls for AML/CFT that, to BlaO’s satisfaction, are in compliance with Applicable Law and consistent with its
business and customer profile and international AML/CFT best practices.

 

5.1.16
Most Favored Lender. If the Borrower or any Subsidiary enters into, amends or modifies documents evidencing or governing Debt
(other than (i) Debt permitted under Section 5.2.12 (Permitted Financial Debt), (ii) Debt incurred under convertible note instruments
issued in connection with equity fundraising, (iii) Debt extended to a Subsidiary of the Borrower by the Borrower or another Subsidiary
of the Borrower, or (iv) if a SPAC Transaction is consummated, Debt extended to the Borrower or a Subsidiary of the Borrower by the Borrower’s
holding company) to which the Borrower or any Subsidiary is bound that contain, or are amended and modified to contain: (a) any covenant,
event of default or remedy that is not provided for in this Agreement or any other Financing Document, or (b) any covenant or Event of
Default that is more restrictive than the same or similar covenant or event of default provided in this Agreement or any other Financing
Document (any or all of the foregoing, collectively, “Most Favored Lender Provisions”), the Borrower shall, at BlaO’s
option and promptly upon request, execute an amendment to this Agreement, in form and substance satisfactory to BlaO, to include such
Most Favored Lender Provisions.

 

5.1.17
Amendment to Merqueo Brazil’s Organizational Documents. Ensure that, within thirty (30) days following the first Disbursement
Date hereunder, the Amendment to Merqueo Brazil’s Organizational Documents, in form and substance satisfactory to BlaO, is duly
adopted and approved by the shareholders of Merqueo Brazil and duly registered with the Board of Trade of the State of São Paulo
(Junta Comercial do Estado de São Paulo) in due course and, in case the Board of Trade of the State of São Paulo
(Junta Comercial do Estado de São Paulo) presents any additional requirements (exigências) in connection with
such registration, duly and timely comply with any such additional requirements (exigências), so that at all times the original
filing number of the Amendment to Merqueo Brazil’s Organizational Documents will be in place to ensure that the effects of such
registration are retroactive to the date of the Amendment to Merqueo Brazil’s Organizational Documents.

 

5.1.18
Relevant Authorizations. Within nine (9) months following the Effective Date, obtain the Authorizations described in Schedule
3.1.4 and provide evidence thereof to BlaO.

 

    - 23 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

5.1.19
Compliance with the Corporate Governance Action Plan. Adopt and comply with the Corporate Governance Action Plan within the relevant
time periods set forth in Schedule 8 (Corporate Governance Action Plan).

 

Section
5.2 Negative Covenants.

 

The Borrower
shall not, and shall cause each of its Subsidiaries not to:

 

5.2.1
Limitation on Restricted Payments. Make any Restricted Payment unless:

 

(i)
such Restricted Payment is made after the date of the First Repayment Date;

 

(ii)
no Default has occurred and is continuing or would exist after giving effect to such Restricted Payment;

 

(iii)
the Borrower is, and, after giving effect to such Restricted Payment, would be, in compliance with Section 5.1.13 (Financial Covenants);
and

 

(iv)
in the case of dividends, distributions on the Share Capital of the Borrower (other than dividends or distributions payable in shares
of the Borrower) or any payment of subordinated debt, such Restricted Payment is made from net income of the current Financial Year or
retained earnings (excluding any amount resulting from the revaluation of any of the Borrower’s assets); provided, that,
for the avoidance of doubt, the foregoing shall not restrict Subsidiaries of the Borrower from making Restricted Payments to the Borrower.

 

5.2.2
No Liens. Create, or permit to exist: (i) any Liens over any of its Property (including Intellectual Property, the Share Capital
of its Subsidiaries, or any trade accounts) other than Permitted Liens; or (ii) any Lien over any of the Borrower’s Share Capital,
to the extent any such Lien is created in connection with the incurrence of debt financing for the benefit of the Borrower or any of
its Subsidiaries (or, if a SPAC Transaction is consummated, for the benefit of the Borrower’s holding company).

 

5.2.3
Maintenance of Existence; Fundamental Changes to the Borrower.

 

(i)
Change its legal form or amend or modify its organizational documents in any manner that materially and adversely affects BlaO’s
rights or remedies under the Financing Documents; and

 

(ii)
Undertake or permit any merger, consolidation, spin-off or reorganization unless: (a) it shall be the surviving entity; and (b) immediately
prior to or after giving effect to such transaction (and treating all liabilities assumed as a result of such transaction as having been
incurred by it at the time of such transaction), no Default shall exist.

 

5.2.4
Affiliate Transactions. Enter into any transaction, including the purchase, sale, lease or exchange of Property or the rendering
of any service, with any Affiliate (an Affiliate Transaction), other than transactions entered into in the ordinary course
of its business on fair and reasonable terms substantially as favorable to the Borrower as those that might be obtained in a comparable
arms-length transaction at the time from a Person who is not an Affiliate.

 

5.2.5
Scope of Business. Change the nature or scope of the Business as of the date hereof, other than businesses reasonably related
or ancillary to the Business.

 

    - 24 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

5.2.6
Accounting Changes. Change its Financial Year or make or permit any change in accounting policies or reporting practices, except
as required to comply with the Accounting Principles or Applicable Law.

 

5.2.7
Prohibited Practices. Commit, engage in, or be involved with (or authorize or permit any Affiliate or any other Person acting
on its behalf to commit, engage in, or be involved with) any Prohibited Practice with respect to any transaction contemplated by any
Financing Document.

 

5.2.8
List of Excluded Activities. Engage in, or be involved with, any activity included in the List of Excluded Activities.

 

5.2.9
Sanctions Lists. Be included on any Internationally Recognized Sanctions Lists or the IDB Group List of Sanctioned Firms and Individuals.

 

5.2.10
Limitation on Transfer of Intellectual Property. Sell, lease, transfer or otherwise dispose of any of its Intellectual Property
(except for (i) any lease or license entered into between the Borrower and/or one or more of its Subsidiaries in the ordinary course
of business and (ii) any license entered into between the Borrower and/or one or more third parties in connection with the services provided
by the Borrower to its customers in the ordinary course of business).

 

5.2.11
No Restriction of Dividends. Directly or indirectly, create or otherwise permit to exist or become effective any restriction on
the ability of any Subsidiary of the Borrower to: (i) pay dividends or make any other distributions on its capital stock or any other
equity interest directly or indirectly owned by the Borrower; or (ii) pay any Financial Debt owed to the Borrower or any of its Subsidiaries;
or (iii) make loans or advances to the Borrower or any of its Subsidiaries except under or by reason of Applicable Laws.

 

5.2.12
Permitted Financial Debt. Incur, assume or permit to exist any Financial Debt other than:

 

(i)
the Senior Loans;

 

(ii)
Financial Debt in the form of a convertible notes entered into between the Borrower and equity investors, so long as each such
convertible note: (a) has an original term of no more than eighteen (18) months; and (b) is mandatorily convertible into Share
Capital at the conclusion of such term;

 

(iii)
Financial Debt incurred in respect of the Warehouse Leases;

 

(iv)
until December 31, 2024:

 

		(a)	Financial
                                            Debt incurred in respect of leases of refrigerators and racks, in an aggregate amount outstanding
                                            at any one time not to exceed three million five hundred thousand Dollars ($3,500,000) or
                                            the equivalent thereof in any other currency; and

 

		(b)	Financial
                                            Debt incurred under working capital lines of credit secured by Cash accounts, in an aggregate
                                            amount outstanding at any one time not to exceed two million Dollars ($2,000,000) or the
                                            equivalent thereof in any other currency; and

 

(v)
after December 31, 2024, Financial Debt so long as the Borrower remains in compliance with Section 5.1.13 (Financial Covenants)
before and after the incurrence of such Financial Debt.

 

    - 25 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

For
the avoidance of doubt, this Section 5.2.12 (1) does not modify, and is without prejudice to the compliance obligations in respect of,
the Financial Covenants and (2) does not apply to trade accounts in the ordinary course of business payable within ninety (90) days.

 

5.2.13
Prepayment of IDB Invest Loan. Make any prepayment of the IDB Invest Loan after the third (3rd) anniversary of the Effective Date
unless the Borrower simultaneously prepays the BlaO Loan on a pro rata basis in accordance with Section 2.4.1 (Voluntary Prepayments).

 

5.2.14
Subsidiaries. Form or own any Subsidiaries (excluding the Guarantors) or otherwise acquire or own any portion of the Share Capital
of any other Person, except that the Borrower may form additional Subsidiaries so long as: (i) prior notice is given thereto to BlaO;
(ii) such Subsidiary enters into a guarantee of the Obligations, substantially similar to the Guarantee Agreement and in form and substance
satisfactory to BlaO; (iii) a pledge over the Share Capital of such newly-formed Subsidiary is granted to the Senior Lenders to secure
the Obligations and the corresponding amounts due in respect of the IDB Invest Loan, in form and substance satisfactory to BlaO; and
(iv) BlaO has received such legal opinions as it may require in connection with the foregoing, including in respect of the enforceability
of the above-described guarantee and share pledge.

 

Section
5.3 Information.

 

The
Borrower shall deliver to BlaO:

 

5.3.1
Audited Annual Financial Statements.

 

(i)
As soon as available but in any event by June 15, 2022, one (1) copy of the Borrower’s Consolidated, and each of its Subsidiaries’
unconsolidated, audited Financial Statements for the 2021 Financial Year setting forth in comparative form the corresponding figures
for the 2020 Financial Year and all associated notes to such statements; and

 

(ii)
as soon as available but in any event within ninety (90) days after the end of each Financial Year thereafter, one (1) copy of the Borrower’s
Consolidated, and each of its Subsidiaries’ unconsolidated, audited Financial Statements for such Financial Year setting forth
in comparative form the corresponding figures for the previous Financial Year and all associated notes to such statements.

 

5.3.2
Unaudited Quarterly Financial Statements. As soon as available but in any event within forty-five (45) days after the end
of each of the four (4) Financial Quarters of each Financial Year: (i) one (1) copy of the unaudited Financial Statements of the Borrower
(on a Consolidated Basis) and each of its Subsidiaries (on an unconsolidated basis) for the Financial Quarter most recently ended as
of such date setting forth in comparative form the corresponding figures for the corresponding periods of the previous Financial Year
and all associated notes to such statement; and (ii) a certificate of an Authorized Representative of the Borrower substantially in the
form of Exhibit 6 (Form of Borrower’s Quarterly Certificate), which shall include an explanation of the key operating
variables and calculations in reasonable detail demonstrating compliance with the Financial Covenants substantially in the form of Exhibit
7 (Form of Financial Ratios Compliance Certificate), or detailing any non-compliance.

 

5.3.3
Notices.

 

(i)
Within five (5) days after receipt (or delivery) by the Borrower or any Subsidiary, copies of all material notices from (or to) any Authority
or otherwise related to or affecting the Borrower or any Subsidiary, the BlaO Loan, the use of Loan proceeds, or the Borrower’s
or any Subsidiary’s ability to perform its obligations hereunder or under any other Financing Documents, including notices from
any Authority seeking to terminate, revoke, suspend or cancel any Relevant Authorization of the Borrower, together with copies of such
notices, if written.

 

    - 26 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(ii)
Promptly (and in any event within five (5) days) upon becoming aware of the occurrence thereof, notice of:

 

		(a)	any
                                            Default, specifying the nature thereof and any steps the Borrower is taking to remedy it;

 

		(b)	any Mandatory
                                            Prepayment Event;

 

		(c)	any
                                            Action (commenced or ongoing) that has had or could reasonably be expected to have a Material
                                            Adverse Effect, specifying the nature of the proceedings and the steps the Borrower is taking
                                            or proposes to take with respect thereto;

 

		(d)	any
                                            actual or proposed material change in the business or operations of the Borrower;

 

		(e)	any
                                            Prohibited Practice by the Borrower, its Affiliates, or any Person acting on its behalf with
                                            respect to the BlaO Loan or any transaction contemplated by this Agreement, or any other
                                            Financing Document, or the imposition by any international financial institution of any sanction
                                            on the Borrower or any Subsidiary for any Prohibited Practice, including any information
                                            in its possession concerning such situation;

 

		(f)	the
                                            commencement of any steps taken in connection with, or in anticipation of: (1) a SPAC Transaction,
                                            any material developments relating thereto, and the conclusion of any such SPAC Transaction;
                                            or (2) the listing of the Borrower’s or its parent company’s Share Capital on
                                            a U.S. securities exchange registered with the U.S. Securities and Exchange Commission and
                                            any material developments relating thereto; and

 

		(g)	any
                                            other event or condition that has had or could reasonably be expected to have a Material
                                            Adverse Effect and the steps the Borrower or the relevant Subsidiary is taking to remedy
                                            it.

 

5.3.4
Communications with Auditor. Promptly upon the Borrower’s receipt thereof, a copy of any management letter or other material
communication sent by the Auditor (or any other accountants retained by the Borrower or any Subsidiary) to the Borrower or any Subsidiary
in relation to the Borrower’s or any Subsidiary’s financial, accounting, management information or other systems, policies,
management or accounts (if not otherwise delivered under this Section 5.3).

 

5.3.5
Impact & Sustainability Indicators.

 

(i)
Within forty-five (45) days after the end of each Financial Year, deliver a report on certain annual impact and sustainability indicators
for such Financial Year in the form of, and with the information listed in, Schedule 3 (Impact & Sustainability Indicators);

 

(ii)
within forty-five (45) days after the end of each Financial Quarter, deliver a report on certain quarterly impact and sustainability
indicators for such Financial Quarter in the form of, and with the information listed in, Schedule 3 (Impact & Sustainability
Indicators);

 

    - 27 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(iii)
within the time periods set forth therein, provide evidence of the completion of the deliverables set forth in the Corporate Governance
Action Plan; and

 

(iv)
upon the full prepayment or repayment of the BlaO Loan, no later than the date of the relevant prepayment or repayment, an updated report
in the form of, and with the information and addressing the topics listed in, Schedule 3 (Impact & Sustainability Indicators).

 

5.3.6
Beneficial Ownership Information. Provide to BlaO, at least annually, and at BlaO’s request, updated information regarding
the direct and indirect ownership of the Borrower to the extent such information is made available to the Borrower by its equity owners
(and, in connection therewith, the Borrower shall use its best efforts to procure the disclosure of such information from its equity
owners).

 

5.3.7
Founders’ Agreements. Provide to BlaO, as soon as available, and at BlaO’s request, copies of any and all of the Founders’
employment or services agreements.

 

5.3.8
Board Presentations. Provide to BlaO, as soon as it is available after the end of each Financial Quarter and each Financial Year,
and at BlaO’s request, the management statements and presentations delivered to the board of directors of the Borrower showing
the financial performance of the Borrower and its Subsidiaries, to the extent that disclosing such information does not create a conflict
of interest for the Borrower or would constitute a breach the Borrower’s confidentiality obligations (as reasonably determined
by the Borrower based on knowledgeable advice from legal counsel).

 

5.3.9
Amendment to Merqueo Brazil’s Organizational Documents. Provide to BlaO, as soon as available, but no later than twenty
(20) days following the date of the Amendment to Merqueo Brazil’s Organizational Documents, a true, correct, complete and fully-executed
copy of the Amendment to Merqueo Brazil’s Organizational Documents, together with evidence of its proper filing with the Board
of Trade of the State of São Paulo (Junta Comercial do Estado de São Paulo).

 

5.3.10
Additional Information. Such information as BlaO may reasonably request with respect to the Borrower or any Subsidiary, its Property,
the BlaO Loan and the Borrower’s and each Subsidiary’s performance of its obligations under the Financing Documents.

 

Section
5.4 Environmental and Social. The Borrower shall deliver to BlaO the information required in Section 5 (E&S Information Covenants)
of Annex 2 (Environmental and Social Provisions).

 

ARTICLE
6

 

Events
of Default

 

Section
6.1 Events of Default.

 

It shall be an Event of Default if:

 

6.1.1
Failure to Pay or Perform under Financing Documents.

 

(i)
The Borrower or any Guarantor fails to pay when due (a) any Obligation, including principal of, or interest on, the BlaO Loan, or (b)
any other loan from BlaO to the Borrower or any Guarantor (other than the BlaO Loan) or any reimbursement obligation in respect of a
guarantee provided by BlaO for the Borrower’s or any Guarantor’s benefit.

 

    - 28 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

(ii)
The Borrower or any of its Subsidiaries fails to perform of observe any term, covenant or agreement contained in Section 2.17 (Notes),
Section 5.1.1 (Use of Proceeds), Section 5.1.2 (Existence; Continuing Engagement in Business), Section 5.1.7 (Ranking
of Obligations), Section 5.1.8 (Environmental and Social Compliance), Section 5.2 (Negative Covenants), and Section
5.3.3 (Notices).

 

(iii)
The Borrower or any of its Subsidiaries fails to comply with any of its other obligations contained in this Agreement or any other Financing
Document or any other agreement between the Borrower and BlaO (other than an obligation referred to elsewhere in this Section 6.1); provided,
that if capable of being cured, such failure has continued for thirty (30) days after the earlier of (a) notice of such failure to comply
being provided by BlaO or (b) the date on which the Borrower or such Subsidiary becomes, or should have become, aware of such failure;
provided further that, for the avoidance of doubt, no cure period shall apply if in the determination of BlaO, such failure has had or
could reasonably be expected to have a Material Adverse Effect.

 

(iv)
Any Financing Document or any material term thereof (a) is revoked, becomes void or ceases to be in full force and effect and enforceable,
(b) becomes unlawful, (c) is repudiated by any party thereto, or (d) has its legality, validity or enforceability challenged by any Person.

 

6.1.2
Failure to Pay or Perform with respect to the IDB Invest Loan. (i) The Borrower fails to pay the IDB Invest Loan or fails to perform
any of its obligations when due or as required under the IDB Invest Loan Agreement and any such failure continues for more than any applicable
period of grace or (ii) the IDB Invest Loan is accelerated, becomes subject to mandatory prepayment or redemption or, prior to its stated
maturity, otherwise becomes due or is placed on demand.

 

6.1.3
Failure to Pay or Perform with respect to Other Debt. (i) The Borrower or any Subsidiary fails to pay any Debt (other than the
Obligations) or fails to perform any of its obligations when due or as required under any agreement pursuant to which there is any outstanding
Debt (other than the Obligations or any Debt described in subclause (i)(b) of Section 6.1.1 and in Section 6.1.2) and any such failure
continues for more than any applicable period of grace, or (ii) any Debt of the Borrower or any Subsidiary (other than the Obligations
or any Debt described in subclause (i)(b) of Section 6.1.1 and in Section 6.1.2) is accelerated, becomes subject to mandatory prepayment
or redemption or, prior to its stated maturity, otherwise becomes due or is placed on demand.

 

6.1.4
Misrepresentation. Any representation or warranty made by the Borrower or any Subsidiary in any Financing Document or in any document
delivered thereunder is found to have been incorrect or misleading in any material respect when made or deemed made (other than in respect
of representations and warranties that were already conditioned as to materiality, in which case, any such representation and warranty
is found to have been incorrect or misleading in any respect when made or deemed made).

 

6.1.5 Expropriation.
Any Authority (i) condemns, nationalizes, confiscates or otherwise expropriates, intervenes, or assumes control of all or any
substantial part of the Property of the Borrower or of any Subsidiary or of its Share Capital or commences a proceeding in
furtherance of any of the foregoing, or (ii) takes any action that would dissolve the Borrower or any Subsidiary, prevent the
Borrower or any Subsidiary from carrying on all or a substantial part of its business or limit the Borrower’s ability to
fulfill its obligations hereunder or under any other Financing Documents.

 

6.1.6
Insolvency Events. Any Insolvency Event occurs.

 

6.1.7
Attachment; Judgments. (i) An attachment or analogous process is levied or enforced against any Property of the Borrower or any
Subsidiary, or (ii) a final judgment, order or arbitral award is rendered against the Borrower or any Subsidiary or any of its Property,
and such attachment, process, judgment, order or arbitral award is for an amount in excess of the equivalent of one million Dollars ($1,000,000).

 

    - 29 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

6.1.8
Failure to Maintain Relevant Authorizations. Any Relevant Authorization ceases to be in full force and effect and is not restored
within thirty (30) days.

 

6.1.9
Material Adverse Effect. Any event occurs or any condition exists that, in the opinion of BlaO, has had, or could reasonably be
expected to have, a Material Adverse Effect.

 

6.1.10
Moratorium. Any Authority of the Borrower’s Country or a Guarantor’s country declares any general payment delay, refusal
to pay or acknowledge a payment obligation or repudiation or other action (whether or not formally announced), which in any such case,
(i) relates to its debts or debts or any category of debts of borrowers in the relevant country not to be paid in accordance with their
terms or (ii) prevents the availability of foreign exchange to the Borrower or any Guarantor for the purpose of performing any material
obligation under this Agreement or any other Financing Document to which it is a party.

 

6.1.11
Security. BlaO ceases to hold for its sole and exclusive benefit a valid first priority perfected security interest in any part
of the Security.

 

6.1.12
Abandonment; Interruption. The Borrower or any Guarantor ceases to carry on the Business for more than thirty (30) continuous
days.

 

Section
6.2 Remedies.

 

If an Event
of Default occurs and is continuing, BlaO may, by written notice to the Borrower, take any or all of the following actions:

 

(i)
suspend or terminate the BlaO Loan Commitment;

 

(ii)
declare the BlaO Loan, or such part of the BlaO Loan as is specified in the notice (with accrued interest thereon), and all other Obligations
to be immediately due and payable (in the case where all Obligations are declared due and payable pursuant to this clause (ii), the Borrower
acknowledges and agrees that, for purposes of Section 2.4.3(i) (Prepayment Fees and Costs), the payment thereof shall be deemed
a prepayment subject to the prepayment fee described in Section 2.4.3(i)); and

 

(iii)
exercise any other remedies that may be available to BlaO under any Financing Document or Applicable Law.

 

Section
6.3 Bankruptcy.

 

If
any Insolvency Event occurs with respect to the Borrower, then (i) the BlaO Loan Commitment shall be automatically terminated, and (ii)
all Obligations arising under this Agreement shall be automatically and immediately due and payable without any presentment, demand,
protest or notice of any kind, all of which the Borrower hereby expressly waives (in the case where all Obligations become due and payable
pursuant to this Section 6.3, the Borrower acknowledges and agrees that, for purposes of Section 2.4.3(i) (Prepayment Fees and Costs),
the payment thereof shall be deemed a prepayment subject to the prepayment fee described in Section 2.4.3(i)).

 

    - 30 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

ARTICLE
7

 

Miscellaneous

 

Section
7.1 Notices.

 

Any
notice, request, demand, approval or other communication to be issued under this Agreement or any other Financing Document shall be in
writing. Subject to Section 7.10.4 (Applicable Law and Jurisdiction), any notice, request, demand or other communication may be
delivered by hand, certified or registered airmail, internationally recognized courier service, or email. Notices shall be deemed to
have been given when received; provided, that email delivery shall be effective only upon receipt of an acknowledgment from the
intended recipient such as by the “return receipt requested” function, as available, reply email or other written acknowledgment;
provided further, that BlaO may at any time require that any notice delivered by email be confirmed by any other means described
herein to the party’s address specified below or at such other address as such party shall have designated by notice to the other
party hereto and shall be effective upon receipt.

 

For
the Borrower:

 

Merqueo
S.A.S.

Carrera
97A No 9A-50

Bogotá,
Colombia

Attention:
Miguel Mc Allister

 

Alternative
address for communications by electronic mail:

miguel@merqueo.com

 

With
a copy (which does not constitute notice) to: 

jmgarcia@merqueo.com

 

For
BlaO:

 

BLUE
LIKE AN ORANGE SUSTAINABLE CAPITAL LATIN AMERICA

HOLDINGS
II S.A.R.L.

5,
Allée Scheffer

L-2520
Luxembourg

Grand
Duchy of Luxembourg

Attention:
Emmanuelle Yannakis

 

Alternative
address for communications by electronic mail:

Emmanuelle.yannakis@blueorangecapital.com

 

Section
7.2 English Language.

 

All
documents to be furnished or communications to be made under this Agreement or any other Financing Document shall be in the English language
and, where any original version of any such document or communication is not in English, shall, if requested by BlaO, be accompanied
by an English translation certified by an Authorized Representative of the Borrower to be a true and correct translation of the original.
BlaO may obtain an official or non-official English or Spanish translation of any Financing Document or any other document or communication
received or prepared in any other language at the Borrower’s expense. BlaO may deem any such translation provided by the Borrower
or otherwise obtained by BlaO to be the governing version.

 

    - 31 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Section
7.3 Indemnity; Waiver of Consequential Damages.

 

7.3.1
The Borrower shall indemnify and hold harmless BlaO and its officers, directors, agents, employees, representatives, attorneys, Affiliates,
successors and assigns (collectively, the “Indemnified Persons”) from and against any and all claims, actions, investigations,
proceedings, suits, judgments, demands, damages (including foreseeable and unforeseeable compensatory damages and punitive claims), losses,
liabilities (including liabilities for penalties), costs and expenses of any nature or kind whatsoever, whether actual or prospective,
and regardless of whether any Indemnified Person is a party thereto, including all court costs and reasonable fees and disbursements
of counsel on a full indemnity basis, arising out of or in connection with: (i) the execution, delivery or enforcement of, or the performance
of any transaction contemplated under, this Agreement or any other Financing Document; (ii) the BlaO Loan or the use of Loan proceeds;
(iii) any Transaction Taxes or Other Taxes arising in connection with payments made under any Financing Document and any liability (including
penalties, additions to tax, interest and expenses) arising therefrom or with respect thereto; (iv) any misrepresentation or omission
with respect to the information provided to BlaO in connection with the BlaO Loan; or (v) any actual or prospective Action relating to
any of the foregoing, whether based on contract, tort or any other theory and regardless of whether any Indemnified Person is a party
thereto (all of the foregoing, collectively, the “Indemnified Liabilities”); provided, that, the Borrower shall
have no obligation hereunder to any Indemnified Person with respect to Indemnified Liabilities arising from the gross negligence or willful
misconduct of any such Indemnified Person as determined by a non-appealable final judgment of a court of competent jurisdiction. The
rights granted under this Section 7.3 are in addition to the rights granted under any other provision of this Agreement, under any other
Financing Document, Applicable Law or otherwise. All amounts due by the Borrower to any Person hereunder shall be due and payable within
five (5) Business Days of demand by such Person. This Section 7.3 shall survive repayment of the Obligations.

 

7.3.2
To the fullest extent permitted by Applicable Law, the Borrower shall not assert, and hereby waives, and acknowledges that no other Person
shall have, any claim against any Indemnified Person, on any theory of liability, for special, indirect, consequential or punitive damages
(as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Financing Document
or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Senior Loan or the use of the
proceeds thereof. No Indemnified Person referred to in Section 7.3.1 shall be liable for any damages arising from the use by unintended
recipients of any information or other materials distributed to such unintended recipients by such Indemnified Person through telecommunications,
electronic or other information transmission systems in connection with this Agreement or any other Financing Documents or the transactions
contemplated hereby or thereby.

 

Section
7.4 Successors and Assigns.

 

7.4.1
This Agreement binds and benefits the respective successors and assignees of the parties; provided, however, that the Borrower
shall not assign or delegate any of its rights or obligations under this Agreement or any other Financing Document without BlaO’s
prior written consent. Any assignment or delegation by the Borrower in violation of this Section 7.4.1 shall be void ab initio.

 

7.4.2
BlaO may, without the need of any notice to or consent from any party or any other action, assign, participate or otherwise allot to
one or more Persons (other than any Person that would qualify as a Competing Business) all or any portion of its rights and obligations
under this Agreement, the Notes and the other Financing Documents.

 

7.4.3
BlaO may not assign at any time, its rights and obligations under this Agreement or any other Financing Document to any Person that would
qualify as a Competing Business; provided, that if an Event of Default occurs and is continuing, BlaO may, without the need of
any notice to or consent from any party or any other action, assign its rights and obligations under this Agreement or any other Financing
Document to any Person that qualifies as a Competing Business (for the avoidance of doubt, without prejudice to BlaO’s rights under
Section 7.4.2).

 

    - 32 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Section
7.5 Counterparts.

 

This
Agreement may be executed in several counterparts, each of which is an original, and all of which together shall constitute one and the
same agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic (i.e., “pdf”
or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement.

 

Section
7.6 Confidential Information.

 

7.6.1
BlaO may disclose any documents or records of, or information relating to, the Borrower, its Subsidiaries, and their Property, business
or affairs to: (i) any Person for the purpose of exercising any power, remedy, right, authority or discretion relevant to this Agreement
or any other Financing Document including in connection with the defense by BlaO of any Action brought by any other party to a Financing
Document; (ii) any Person pursuant to Applicable Law; (iii) any banking or other regulatory or examining authorities (whether governmental
or otherwise) pursuant to and in accordance with whose instructions it and other banks must customarily comply; (iv) the directors, officers,
employees, arrangers, co-lenders, attorneys, consultants, rating agencies, independent auditors and advisors (including any technical,
financial and other advisors) of BlaO and IDB Invest, and their respective affiliates or related Persons; and (v) any Person in connection
with any proposed sale, transfer, assignment, insurance, coverage or other disposition of BlaO’s rights under this Agreement or
any other Financing Document.

 

7.6.2
The Borrower expressly authorizes BlaO to request from any Person information relating to the Borrower, and the Borrower agrees to hold
each such Person harmless and exempt from any and all liability under Applicable Law in connection with the request for, and disclosure
of, such information by such Person.

 

7.6.3
The Borrower acknowledges and agrees that, notwithstanding any other agreement between the Borrower and BlaO, disclosure by any such
Person of any documents or records of, or information relating to, the Borrower, its Property, business or affairs in the circumstances
contemplated by this Section 7.6 does not violate any duty owed to the Borrower by such Person under this Agreement, any other Financing
Document or any such other agreement.

 

Section
7.7 Amendment.

 

Any
amendment or waiver of, or any consent given under, this Agreement shall be effective only if in writing and, in the case of any amendment,
signed by the Borrower and BlaO or their permitted successors and assigns.

 

Section
7.8 Savings of Rights; Remedies; No Waiver.

 

7.8.1
The rights and remedies of BlaO in relation to any misrepresentation or breach of warranty by the Borrower shall not be prejudiced by
any investigation by or on behalf of BlaO into the Borrower’s affairs, by the execution or the performance of this Agreement or
by any other act or thing that may be done by or on behalf of BlaO in connection with this Agreement and that might, apart from this
Section 7.8, prejudice such rights or remedies.

 

    - 33 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

7.8.2
No course of dealing or waiver by BlaO in connection with any condition of Disbursement under this Agreement shall impair any right,
power or remedy of BlaO with respect to any other condition of Disbursement, or be construed to be a waiver thereof.

 

7.8.3
No course of dealing and no failure or delay by BlaO in exercising, in whole or in part, any power, remedy, discretion, authority or
other right under this Agreement or any other Financing Document shall waive or impair, or be construed to be a waiver of or an acquiescence
in, such or any other power, remedy, discretion, authority or right under this Agreement, or in any manner preclude its additional or
future exercise, nor shall the action of BlaO with respect to any default, or any acquiescence by it therein, affect or impair any right,
power or remedy of BlaO with respect to any other default. The rights and remedies provided in this Agreement are cumulative and not
exclusive of any remedies provided by Applicable Law.

 

Section
7.9 Severability. Any provision hereof that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof and without affecting
the validity or enforceability of such provision in any other jurisdiction. Where terms of any Applicable Law resulting in such prohibition
or unenforceability may be waived contractually, they are hereby waived by the parties hereto to the full extent permitted by Applicable
Law so that this Agreement may be deemed valid, binding and enforceable in its entirety in accordance with its terms.

 

Section
7.10 Applicable Law and Jurisdiction.

 

7.10.1
This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York of the United States of America
without regard to any conflict of laws principles thereof that would result in the general application of the law of any other jurisdiction.

 

7.10.2
The Borrower hereby irrevocably and unconditionally submits, for itself and its Property, to the non-exclusive jurisdiction of the courts
of the State of New York sitting in the Borough of Manhattan and of the United States of America District Court for the Southern District
of New York, and any appellate court from any thereof, in any Action arising out of or relating to this Agreement or any other Financing
Document (other than the Notes and any Security Document) to which the Borrower is a party. Final judgment against the Borrower in any
such Action shall be conclusive and may be enforced in any other jurisdiction including the Borrower’s Country by suit on the judgment,
a certified or exemplified copy of which shall be conclusive evidence of the judgment, or in any other manner provided by Applicable
Law.

 

7.10.3
Nothing in this Agreement shall affect BlaO’s right to commence legal proceedings or otherwise sue the Borrower in the Borrower’s
Country, in any other appropriate jurisdiction or concurrently in more than one jurisdiction or to serve process, pleadings and other
legal papers upon the Borrower in any manner authorized by the laws of any such jurisdiction.

 

7.10.4
The Borrower agrees irrevocably to designate, appoint and empower Registered Agents Inc., with offices at 90 State Street, Suite 700,
Office 40, Albany, New York, NY 12207, or such other Person located in the State of New York that BlaO approves is acceptable to it,
as the Borrower’s authorized agent (the “Process Agent”) to receive on its behalf service of legal process in
any Action that BlaO may bring in respect of this Agreement or any other Financing Document to which the Borrower is a party in any court
specified in Section 7.10.2 above.

 

7.10.5
The Borrower shall, for so long as this Agreement is in effect, maintain a duly appointed and authorized agent in the State of New York
acceptable to BlaO to receive for and on its behalf service of summons, complaint or other legal process in any Action that BlaO may
bring in the State of New York in respect of this Agreement or any other Financing Document to which the Borrower is a party and shall
keep BlaO advised of the identity and location of such agent.

 

    - 34 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

7.10.6
The Borrower further irrevocably consents that, if for any reason the Borrower has no authorized agent for service of process in the
State of New York, then service of process may be made out of the courts referred to in Section 7.10.2 by mailing copies thereof by registered
United States of America mail to the Borrower at its address specified in Section 7.1 (Notices). BlaO shall also send the Borrower
by email a copy of any such process.

 

7.10.7
Service of process in the manner provided in this Section 7.10 in any Action shall be deemed personal service, accepted by the Borrower
as such, and shall be valid and binding upon the Borrower for all the purposes of any such Action.

 

7.10.8
The Borrower irrevocably waives, to the fullest extent permitted by Applicable Law: (i) any objection that it may now or hereafter have
to the laying of venue of any Action brought in any court referred to in this Section 7.10; (ii) any claim that any such Action brought
in any such court has been brought in an inconvenient forum; and (iii) its right of removal of any matter commenced by BlaO in the courts
of the State of New York to any court of the United States of America.

 

7.10.9
To the extent that the Borrower may, in any Action brought in any of the courts referred to in Section 7.10.2, a court of the Borrower’s
Country or elsewhere arising out of or in connection with this Agreement, the Notes or any other Financing Document to which it is a
party, be entitled to the benefit of any provision of law requiring BlaO in such Action to post security for the costs of the Borrower
or to post a bond or to take similar action, the Borrower hereby irrevocably waives such benefit to the fullest extent now or hereafter
permitted under the Applicable Law of the jurisdiction in which such court is located.

 

7.10.10 
To the extent that the Borrower may be entitled in any jurisdiction to claim immunity for itself or its Property from any suit,
execution, attachment (whether provisional or final, in aid of execution, before judgment or otherwise) or other legal process or to
the extent that in any jurisdiction that immunity (whether or not claimed) may be attributed to it or its Property, the Borrower irrevocably
agrees not to claim and irrevocably waives such immunity to the fullest extent permitted now or in the future by the laws of such jurisdiction.

 

7.10.11 
TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, THE BORROWER
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING RELATING
TO THIS AGREEMENT OR ANY OTHER FINANCING DOCUMENT TO WHICH THE BORROWER IS A PARTY OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

7.10.12
The parties have participated jointly in the negotiation and drafting of this Agreement and the other Financing Documents. The Borrower
expressly acknowledges that it has had the opportunity to retain and consult with counsel of its choice admitted under the laws of the
State of New York and that it has elected not to retain such counsel in connection with the negotiation and drafting of this Agreement
and each other Financing Document governed by New York law. If an ambiguity or question of intent or interpretation arises, this Agreement
and the other Financing Documents shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any other Financing Document,
the relative bargaining power of the parties or the Borrower’s failure to retain counsel admitted under the laws of the State of
New York.

 

    - 35 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Section
7.11 Set-Off.

 

In
addition to any rights and remedies of BlaO provided by Applicable Law, BlaO shall have the right upon any Obligation becoming due and
payable by the Borrower (whether at stated maturity, by acceleration or otherwise) to set-off, appropriate and apply against any Obligation
any deposits in any currency, and any other credits, indebtedness or claims in any currency, at any time held or owing by BlaO to or
for the credit of the Borrower.

 

Section
7.12 Entire Agreement.

 

This
Agreement and the other Financing Documents represent the final and complete agreement of the parties hereto with respect to the BlaO
Loan, and all prior negotiations, representations, understandings, writings and statements of any nature with respect thereto are hereby
superseded in their entirety by the terms of this Agreement and the other Financing Documents.

 

Section
7.13 No Third-Party Beneficiary.

 

Except
as otherwise expressly provided in this Agreement, nothing contained in this Agreement shall be construed to create any right in, duty
to, standard of care with respect to, or any liability to any Person who is not a party to this Agreement.

 

Section
7.14 Survival.

 

All
representations and warranties made in this Agreement, in any other Financing Document and in any document, certificate or statement
delivered pursuant hereto or in connection herewith and Section 2.6 (Currency and Place of Payment), Section 2.9 (Taxes),
Section 2.12 (Payment of Fees, Costs and Expenses), Section 7.3 (Indemnity; Consequential Damages), and Section 7.10 (Applicable
Law and Jurisdiction), together with any related provisions in Article 1 (Definitions; Interpretation) and definitions in
Annex 1 (Definitions), shall survive and remain in full force and effect regardless of the consummation of the transactions
contemplated hereby, the repayment in full or expiration or termination of the BlaO Loan or the termination of this Agreement or any
other Financing Document or any provision hereof or thereof.

 

Section
7.15 Term of Agreement.

 

This
Agreement shall continue in force until the date on which BlaO is satisfied that (i) all amounts outstanding under the Financing Documents
have been indefeasibly paid and discharged in full and (ii) BlaO is under no obligation to make any further Disbursement under this Agreement
or any other Financing Document.

 

(Signature
pages follow)

 

    - 36 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

IN
WITNESS WHEREOF, the parties, acting through their duly Authorized Representatives, have caused this Agreement to be signed in their
respective names, on the date first above written.

 

	MERQUEO S.A.S.,	 
	as Borrower	 
	 	 
	By:	/s/
    Miguel Mc Allister	 
	Name: 	Miguel Mc Allister Reyes	 
	Title: 	CEO	 

 

    - 37 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

Blue like
an Orange Sustainable Capital - Latin America Holdings II S.A.R.L.

as lender of the BlaO Loan

 

	By:	/s/
    Bertrand Badre	 
	Name:  	Bertrand Badre	 
	Title:	Chief Executive Officer - Partner	 
	 	 
	By:	/s/ Emmanuelle
    Yannakis	 
	Name: 	Emmanuelle Yannakis	 
	Title: 	Chief Financial Officer
    - Partner	 

 

    - 38 -
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

ANNEX
1

 

DEFINITIONS

General
Definitions.

 

“Acceptable
Auditor” means any internationally recognized independent public accountants acceptable to BlaO.

 

“Accounting
Principles” means International Financial Reporting Standards (formerly International Accounting Standards) (IFRS) promulgated
by the International Accounting Standards Board (IASB), together with its pronouncements thereon from time to time, applied on a consistent
basis.

 

“Action”
means any action, claim, suit, other legal proceeding, arbitral proceeding, administrative proceeding, investigation or other claim.

 

“Additional
Interest” has the meaning given to that term in Section 2.14 (Additional Interest).

 

“Additional
Interest Calculation Period” means, in respect of the calculation of the Additional Interest, either (i) the six (6)-month
period from January 1 through June 30 of the relevant Financial Year, or (ii) the relevant Financial Year, as the context may require.

 

“Affiliate”
means, with respect to any Person, any other Person directly or indirectly Controlling, Controlled by or under common Control with such
Person.

 

“Agreement”
has the meaning provided in the preamble hereto.

 

“Amendment
to Merqueo Brazil’s Organizational Documents” means an amendment to the articles of association of Merqueo Brazil, duly
executed by the Borrower and Merqueo International as shareholders of Merqueo Brazil, in which a provision will be included stating the
existence of the Security over the shares of Merqueo Brazil pursuant to the terms and conditions of the relevant Security Document.

 

“AML/CFT”
means anti-money laundering and combating the financing of terrorism.

 

“Applicable
Law” means any applicable statute, code, rule, regulation, treaty having the force of law, judgment, common or customary law
or similar governmental restriction or directive by any Authority, in each case, as amended, re-enacted or replaced from time to time.

 

“Applicable
Spread” means nine percent (9.0%) per annum; provided, that beginning with the 2023 Financial Year, such rate shall
be increased by one and one half percent (1.5%) for each Financial Year in which Consolidated EBITDA is not positive, with such increase
effective as of the commencement of the first Interest Period beginning after the conclusion of each such Financial Year; provided
further, that in no event shall such rate exceed twelve and one half percent (12.5%) per annum.

 

    Annex 1-1
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Applicable
Term SOFR” means Term SOFR published by the Term SOFR Administrator on the relevant Interest Rate Determination Date and corresponding
to the prevailing:

 

		(i)	one-month
                                            Term SOFR, if the period from the relevant Interest Payment Date to the next Interest Payment
                                            Date is between one (1) and sixty (60) days;

 

		(ii)	three-month
                                            Term SOFR, if the period from the relevant Interest Payment Date to the next Interest Payment
                                            Date is between sixty-one (61) and one hundred thirty-five (135) days; or

 

		(iii)	six-month
                                            Term SOFR, if the period from the relevant Interest Payment Date to the next Interest Payment
                                            Date is more than one hundred and thirty-five (135) days;

 

provided
that:

 

		(a)	when
                                            determining Applicable Term SOFR for the last Interest Period of the BlaO Loan, the reference
                                            period for Applicable Term SOFR shall be the same as the reference period for the preceding
                                            Interest Period;

 

		(b)	if
                                            as of 5:00 p.m. (New York City time) on any Interest Rate Determination Date, Term SOFR for
                                            the relevant tenor has not been published by the Term SOFR Administrator and a Benchmark
                                            Replacement Date with respect to Applicable Term SOFR has not occurred, then Applicable Term
                                            SOFR will be the Term SOFR for such tenor as published by the Term SOFR Administrator on
                                            the first preceding Business Day for which such Term SOFR was so published, so long as such
                                            first preceding Business Day is not more than three (3) Business
Days prior to such Interest Rate Determination Date; and

 

		(c)	if
                                            Applicable Term SOFR determined as provided above is in any event ever less than the Floor,
                                            then Applicable Term SOFR shall be deemed to be the Floor.

 

“Auditor”
means Ernst & Young or any replacement Acceptable Auditor appointed by the Borrower as its auditor from time to time in accordance
with this Agreement.

 

“Authority”
means any supranational, national, regional or local government or political subdivision thereof, or any governmental, administrative,
executive, legislative, arbitral, regulatory, fiscal or judicial body, department, commission, authority, tribunal or agency, or any
superintendency, monetary authority or central bank, including the supervisory authority for banking and other financial institutions,
and any Person, whether or not government-owned and howsoever constituted or called, that exercises the functions of any such entity
or claims to have jurisdiction over such matters.

 

“Authorization”
means any consent, license or approval (howsoever evidenced), registration, filing, notarization, certificate or exemption from, by or
with any Authority, and all corporate, Shareholders’, creditors’ and any other third-party approvals or consents.

 

“Authorized
Representative” means, as to any Person, any individual who is duly authorized by such Person to act for such Person, or with
respect to financial matters, the chief financial officer or treasurer of such Person, and in the case of the Borrower or any Guarantor,
in addition to the foregoing, an officer duly appointed to act on the Borrower or such Guarantor’s behalf under corporate documents
duly registered with the competent Authority in the Borrower’s Country or other relevant jurisdiction and any Person whose name
and specimen signature appear on the Certificate of Incumbency and Authority most recently delivered by the Borrower to BlaO (including,
for the avoidance of doubt, in the case of Merqueo Mexico, an attorney-in-fact duly appointed and authorized).

 

“Benchmark”
means, initially, Applicable Term SOFR; provided, that if a Benchmark Transition Event has occurred with respect to Applicable
Term SOFR or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such
Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.16 (Benchmark Replacement Setting).

 

    Annex 1-2
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Benchmark
Replacement” means the sum of: (i) the alternate benchmark rate that has been selected by BlaO giving due consideration to
(a) any selection or recommendation of a replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body
at such time or (b) any evolving or then-prevailing market convention for determining a rate of interest for Dollar-denominated syndicated
or bilateral credit facilities; and (ii) the Benchmark Replacement Adjustment; provided that, if at any time the Benchmark Replacement
as so determined would be less than zero, the Benchmark Replacement will be deemed to be zero for the purposes of this Agreement and
any other Financing Document.

 

“Benchmark
Replacement Adjustment” means, for each applicable Interest Period, the spread adjustment, or method for calculating or determining
such spread adjustment, (which may be a positive or negative value or zero) that has been selected by BlaO giving due consideration to
(i) any selection or recommendation of a replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body
at such time or (ii) any evolving or then-prevailing market convention for determining a rate of interest for Dollar-denominated syndicated
or bilateral credit facilities.

 

“Benchmark
Replacement Conforming Changes” means, with respect to any Benchmark Replacement, any technical, administrative or operational
changes (including changes to the definition of Interest Period, the timing and frequency of determining rates and making payments of
interest and other administrative matters) that BlaO decides may be appropriate to reflect the adoption and implementation of such Benchmark
Replacement and to permit the administration thereof by BlaO in a manner substantially consistent with market practice (or, if BlaO decides
that adoption of any portion of such market practice is not administratively feasible or if BlaO determines that no market practice for
the administration of the Benchmark Replacement exists, in such other manner of administration as BlaO decides is reasonably necessary
in connection with the administration of the BlaO Loan and this Agreement).

 

“Benchmark
Replacement Date” means the date on which a Benchmark Replacement becomes effective pursuant to Section 2.16 (Benchmark
Replacement Setting).

 

“Benchmark
Transition Event” means the occurrence of one or more of the following events:

 

		(i)	a
                                            public statement or publication of information by the regulatory supervisor for the administrator
                                            of the Benchmark announcing that the Benchmark is no longer representative;

 

		(ii)	the
                                            administrator of the Benchmark permanently or indefinitely ceases to provide the Benchmark;
                                            provided, that, at the time of such cessation, there is no successor administrator
                                            that will continue to provide the Benchmark; or

 

		(iii)	the
                                            determination by BlaO that, in anticipation of the withdrawal of regulator support for the
                                            Benchmark, the use of one or more alternative benchmarks has become conventional in the market
                                            for Dollar-denominated floating rate syndicated or bilateral credit facilities.

 

“BlaO”
has the meaning provided in the preamble hereto.

 

“BlaO
Loan” has the meaning given to such term in in Section 2.1.1 (The BlaO Loan).

 

“BlaO
Loan Commitment” has the meaning given to such term in in Section 2.1.1 (The BlaO Loan).

 

“Board
of Directors” means, as to any Person, the board of directors of such Person or such other body performing similar functions
with respect to such Person.

 

“Borrower”
has the meaning provided in the preamble hereto.

 

    Annex 1-3
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Borrower’s
Country” means the Republic of Colombia.

 

“Brazil”
means the Federative of Republic of Brazil.

 

“Business”
means the business of maintaining one or more websites for the online ordering and physical delivery of grocery goods in Latin America.

 

“Business
Day” means (i) any day that is not a Saturday, Sunday or other day that is a legal holiday under the laws of the State of New
York or the laws of the Republic of Colombia, or is a day on which banking institutions in New York or Colombia are authorized or required
by Applicable Law to close, and (ii) solely for the purpose of determining Applicable Term SOFR, a U.S. Government Securities Business
Day.

 

“Certificate
of Incumbency and Authority” means a certificate provided to BlaO by the Borrower in the form of Exhibit 5 (Form
of Borrower’s Certificate of Incumbency and Authority).

 

“Change
in Law” means the occurrence, after the Effective Date (including any circumstance that is retroactive to a date prior to the
Effective Date), of any of the following: (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in
any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Authority
or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Authority;
provided, that notwithstanding anything herein to the contrary, (a) the Dodd-Frank Wall Street Reform and Consumer Protection
Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (b) all requests, rules, guidelines
or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or
similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be
deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued.

 

“Change
of Control” means the occurrence of any of the following: (i) any Person holds, of record or beneficially, and possess the
ability to vote (whether directly or indirectly) more than fifty percent (50%) of each class of outstanding Share Capital entitled to
voting rights with respect to the Borrower free and clear of all Liens; (ii) any Person acquires Control of the Borrower; or (iii) the
Borrower enters into any management, partnership, profit-sharing, joint-venture or royalty agreement or other similar agreement whereby
its business or operations or that of its Subsidiaries are managed by, or a significant part of its or their net income or profits are
shared with, any Person.

 

“Colombian
Pesos” means the lawful currency of the Borrower’s Country.

 

“Commitment Fee” has the meaning given
to that term in Section 2.12.1(i) (Fees).

 

“Commitment
Termination Date” means the earliest of: (i) the first anniversary of the Effective Date; (ii) the date the BlaO Loan
Commitment is cancelled in full in accordance with the terms of Section 2.10 (Suspension of Disbursements; Cancellation of BlaO
Loan Commitment); (iii) the date of any prepayment of any part of the BlaO Loan; and (iv) any other date on which the BlaO Loan
Commitment and the Borrower’s right to request further Disbursements are terminated in accordance with the terms of this
Agreement; provided, that in the case of the Interest Reserve Amount only, if the Commitment Termination Date occurs pursuant
to clauses (i) through (iv) above on any date on which any principal amount of the BlaO Loan remains outstanding and is not due and
owing, then the Commitment Termination Date for the Interest Reserve Amount shall instead be the date falling sixty (60) days after
the expiration of the Interest Reserve Period.

 

    Annex 1-4
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Competing
Business” means any entity satisfying both of the following conditions: (a) one or any of its operating businesses is an online
grocery retailer or grocery service provider; and (b) its business operations are primarily located in Latin America (including, for
the avoidance of doubt, Mexico).

 

“Control”
means, with respect to any Person, any other Person having the power, directly or indirectly, (i) 
to vote more than fifty percent (50%) of the securities having ordinary voting power including for the election of directors of
such Person; (ii) to appoint the majority of the administrators of such Person; (iii) to appoint a majority of the members of such Person’s
Board of Directors; or (iv) to establish, direct or cause the direction of the management or policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; (“Controlling” and “Controlled”
have corresponding meanings).

 

“Corporate
Governance Action Plan” means the corporate governance action plan(s) developed by the Borrower, a copy of which is attached
as Schedule 8 (Corporate Governance Action Plan).

 

“Costs”
means any costs, expenses or losses incurred by BlaO in connection with the BlaO Loan, with any determinations thereof being made by
BlaO, including: (i) any breakage of funds, termination costs and other unwinding costs, if positive, incurred by BlaO, taking into account
the principal repayment schedule, the first scheduled repayment date for the BlaO Loan and the applicable Loan Final Maturity Date for
the BlaO Loan; (ii) interest paid and/or payable to cover any unpaid amount; (iii) broken funding and redeployment costs; (iv) any foreign
exchange loss and/or hedge liquidation costs; and (v) any loss, premium, penalty and expense that may be incurred in liquidating or employing
deposits of, and/or borrowings from, third parties in order to fund and/or maintain all or any part of the BlaO Loan.

 

“Debt”
means, with respect to any Person, the aggregate (as of the date of calculation) of all such Person’s obligations (whether actual
or contingent) to pay or repay money, including:

 

		(i)	all
                                            Financial Debt;

 

		(ii)	any
                                            credit to such Person from a supplier of goods or services provided by deferral of the purchase
                                            price or under any installment purchase or other similar arrangement in respect of goods
                                            or services (except trade accounts in the ordinary course of business payable within ninety
                                            (90) days);

 

		(iii)	all
                                            liabilities of such Person (actual or contingent) under any conditional sale or a transfer
                                            with recourse or obligation to repurchase, including by way of discount or factoring of book
                                            debts or receivables;

 

		(iv)	all
                                            obligations of others secured by (or for which the holder of such obligation has an existing
                                            right, contingent or otherwise, to be secured by) any Lien on Property owned or acquired
                                            by such Person, whether or not the obligation secured thereby has been assumed; and

 

		(v)	the
                                            amount of any obligation in respect of any guarantee or indemnity for any of the foregoing
                                            items (other than Financial Debt) incurred by any other Person.

 

“Default”
means any event or condition that constitutes an Event of Default or any event or condition that, but for notice, lapse of time or the
making of a determination, or any combination thereof, would constitute an Event of Default.

 

    Annex 1-5
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Derivative
Transaction” means any swap agreement, cap agreement, collar agreement, futures contract, forward contract, option contract,
or similar arrangement with respect to interest rates, currencies or commodity prices.

 

“Disbursement”
means any disbursement of the BlaO Loan.

 

“Disbursement
Account” means the bank account in the Republic of Panama and corresponding wire instructions provided in Exhibit 1
(Form of Disbursement Request) or any other bank account notified by the Borrower to BlaO on or prior to the delivery of any Disbursement
Request.

 

“Disbursement
Date” means the date on which the proceeds of a Disbursement are released by BlaO to the Borrower, which shall be a Business
Day prior to the Commitment Termination Date on which BlaO is open for business.

 

“Disbursement
Request” means a request for a Disbursement delivered by the Borrower to BlaO substantially in the form of Exhibit 1
(Form of Disbursement Request).

 

“Dollars”
and the sign “$” mean the lawful currency of the United States of America.

 

“Effective Date” has
the meaning provided in the preamble hereto.

 

“Equity
Rights” means, in respect of a Person (other than an individual) any subscriptions, subscription bonuses, options, warrants,
commitments, preemptive rights or agreements of any kind (including any shareholders’ or voting trust agreements) for the issuance,
subscription, sale, registration or voting of, or any securities convertible into, any Share Capital of such Person.

 

“Event
of Default” means any event specified in Section 6.1 (Events of Default).

 

“Fee
Letter” means each fee letter agreement to be entered into between each Senior Lender and the Borrower setting forth the fees
payable in respect of the transactions contemplated herein and the other Financing Documents.

 

“Financial
Covenants” has the meaning provided in Section 5.1.13 (Financial Covenants).

 

“Financial Debt” means
all of the Borrower’s and its Subsidiaries’ obligations in respect of:

 

		(i)	borrowed
                                            money, including the BlaO Loan;

 

		(ii)	the
                                            outstanding principal amount of any bonds, notes, loan stock, commercial paper, acceptance
                                            credits, debentures and bills or promissory notes drawn, accepted, endorsed or issued by
                                            the Borrower or any Subsidiary;

 

		(iii)	non-contingent
                                            obligations of the Borrower or any Subsidiary to reimburse any other Person in respect of
                                            amounts paid under a letter of credit, bank guarantee or similar instrument (excluding any
                                            such letter of credit or similar instrument issued for the Borrower’s or any Subsidiary’s
                                            account in respect of trade accounts incurred and payable in the ordinary course of business
                                            to trade creditors within ninety (90) days of the date that they are incurred and which are
                                            not overdue);

 

    Annex 1-6
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

		(iv)	the
                                            amount of any obligation in respect of any capitalized leases to the extent such obligation
                                            is required to be capitalized and accounted for as a financial obligation of capital lease
                                            on a balance sheet of such Person under the Accounting Principles;

 

		(v)	amounts
                                            raised under any other transaction having the commercial effect of a borrowing and that would
                                            be classified as a borrowing (and not as an off-balance sheet financing) under the Accounting
                                            Principles including under leases or similar arrangements entered into primarily as a means
                                            of financing the asset leased;

 

		(vi)	the
                                            amount of the Borrower’s and its Subsidiaries’ obligations under any Derivative
                                            Transactions entered into in connection with the protection against or benefit from fluctuation
                                            in any rate or price (but only the net amount owing by the Borrower or its Subsidiaries after
                                            marking the relevant derivative transactions to market);

 

		(vii)	any
                                            premium payable on a redemption or replacement of any of the foregoing items; and

 

		(viii)	the
                                            amount of any obligation in respect of any guarantee or indemnity for any of the foregoing
                                            items incurred by any other Person.

 

“Financial
Quarter” means each period commencing on the day after a Financial Quarter Date and ending on the immediately succeeding Financial
Quarter Date.

 

“Financial
Quarter Date” means each March 31, June 30, September 30 and December 31.

 

“Financial
Year” means the accounting year of the Borrower and its Subsidiaries commencing each year on January 1 and ending on the following
December 31 or such other period as the Borrower, with BlaO’s consent, designates as its accounting year.

 

“Financing
Documents” means, collectively:

 

		(i)	this
                                            Agreement;

 

		(ii)	the
                                            IDB Invest Loan Agreement;

 

		(iii)	each
                                            Note;

 

		(iv)	the
                                            Security Documents;

 

		(v)	the
                                            Guarantee Agreement;

 

		(vi)	the
                                            IDB Invest Guarantee Agreement;

 

		(vii)	the
                                            fee letters between the Borrower and each Senior Lender;

 

		(viii)	all
                                            documents relating to the BlaO Loan or the IDB Invest Loan that are entered into after the
                                            Effective Date and designated as a Financing Document by BlaO and the Borrower or IDB Invest
                                            and the Borrower; and

 

		(ix)	all
                                            other documents and certificates required to be delivered from time to time hereunder and
                                            thereunder.

 

    Annex 1-7
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“First
Repayment Date” means the first Interest Payment Date immediately following the date falling thirty (30) months after the first
Disbursement Date.

 

“Floor”
means zero percent (0%) per annum.

 

“Founders”
means, together, Miguel Mc Allister, José Guillermo Calderón, Pablo González, and Sebastián Noguera.

 

“Guarantee
Agreement” means an agreement entered into, or to be entered into, between the Guarantors and BlaO relating to the Guarantors’
primary, unconditional and irrevocable guarantee in favor of BlaO of all of the Borrower’s payment obligations to BlaO under the
Financing Documents.

 

“Guarantors”
means Merqueo Brazil, Merqueo International, and Merqueo Mexico.

 

“IDB”
means the Inter-American Development Bank, an international organization established by the Agreement Establishing the Inter-American
Development Bank among its member countries.

 

“IDB
Group” means IDB Invest, IDB and the Multilateral Investment Fund.

 

“IDB
Group List of Sanctioned Firms and Individuals” means the list of firms and individuals listed in, and accessible at:
http://www.iadb.org/en/topics/transparency/integrity-at-the-idb-group/sanctioned-firms-and-individuals,1293.html or any successor
website or location.

 

“IDB
Invest” means the Inter-American Investment Corporation, an international organization established by the Agreement Establishing
the Inter-American Investment Corporation among its member countries as lender of the IDB Invest Loan.

 

“IDB
Invest Guarantee Agreement” means an agreement entered into, or to be entered into, between the Guarantors and IDB Invest relating
to the Guarantors’ primary, unconditional and irrevocable guarantee in favor of IDB Invest of all of the Borrower’s payment
obligations to IDB Invest under the Financing Documents.

 

“IDB
Invest Loan” means a loan in an aggregate amount of up to the IDB Invest Loan Commitment to be funded by IDB Invest or, as
the context may require, the outstanding principal amount thereof.

 

“IDB
Invest Loan Agreement” means the agreement to be entered into between the Borrower and IDB Invest on or about the date hereof
providing for the IDB Invest Loan Commitment.

 

“IDB
Invest Loan Commitment” means the four million Dollar ($4,000,000) loan commitment to be made by IDB Invest to the Borrower
pursuant to the IDB Invest Loan Agreement.

 

“IDB
Invest Members” means the member countries of IDB Invest listed in Schedule 1 (Member Countries of IDB Invest).

 

“IDB
Invest Put Option Agreement” means the Put Option Agreement dated as of June 4, 2021 among IDB Invest, IDB Invest acting as
agent for IDB as administrator of the Clean technology Fund II, the Borrower and the Guarantors.

 

    Annex 1-8
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Increased
Costs” means the amount certified in an Increased Costs Certificate to be the net incremental costs of, or reduction in return
to, BlaO in connection with making or maintaining the BlaO Loan that results from:

 

		(i)	any
                                            Change in Law; or

 

		(ii)	any
                                            compliance with any request from, or requirement of, any central bank or other monetary or
                                            other Authority; or

 

		(iii)	if
                                            the Interest Rate is calculated in accordance with Section 2.15 (Market Disruption),
                                            Increased Costs shall also include any difference between the Market Disruption Base Rate
                                            and the actual cost to BlaO of making, funding or maintaining the BlaO Loan for the relevant
                                            Interest Period;

 

that
in any such case, subsequent to the Effective Date:

 

		(a)	imposes,
                                            modifies or makes applicable any reserve, special deposit, compulsory loan, insurance charge
                                            or similar requirements against Property of, or deposits with or for the account of, or credit
                                            extended by BlaO;
	 	 	 

		(b)	imposes
                                            a cost on BlaO as a result of its having made or committed to make the BlaO Loan or reduces
                                            the rate of return on the overall capital of BlaO that it would have been able to achieve
                                            had it not made or committed to make the BlaO Loan;
	 	 	 

		(c)	subjects
                                            BlaO to any Tax in respect of the BlaO Loan (other than a change in taxation of the overall
                                            net income of BlaO imposed by a jurisdiction to which BlaO is subject); or
	 	 	 

		(d)	imposes
                                            on BlaO any other cost or condition regarding the making or maintaining of the BlaO Loan.

 

“Increased
Costs Certificate” means a certificate furnished by BlaO to the Borrower certifying: (a) the circumstances giving rise to the
Increased Costs; (b) that the costs of BlaO have increased or its rate of return has been reduced; (c) the amount of Increased Costs;
and (d) that BlaO has exercised reasonable efforts to minimize or eliminate the relevant increase or reduction; provided, that
BlaO shall not be obliged to disclose any information that any Lender considers to be confidential in providing such certificate.

 

“Indemnified
Liabilities” has the meaning provided in Section 7.3 (Indemnity; Waiver of Consequential Damages).

 

“Indemnified
Persons” has the meaning provided in Section 7.3 (Indemnity; Waiver of Consequential Damages).

 

“Insolvency
Event” means any of the following: (i) a court declares the Borrower or any Subsidiary bankrupt or insolvent; (ii) a petition
seeking reorganization, intervention, surveillance, moratorium, liquidation, arrangement, adjustment, concurso or composition
of or in respect of the Borrower or any Subsidiary under any Applicable Law is properly filed; (iii) a court appoints a receiver, liquidator,
trustee, sequestrator, assignee, síndico, interventor (or similar official) of the Borrower or any Subsidiary or
of any substantial part of its Property or Debt or orders the winding up, dissolution, re-organization or liquidation of its affairs;
(iv) the Borrower or any Subsidiary itself takes any action to institute proceedings to be adjudicated bankrupt or insolvent, or consents
to the commencement of bankruptcy or insolvency proceedings against it, or files a petition or answer or consent seeking reorganization
or similar relief under any Applicable Law, or consents to the filing of any such petition or to the appointment of a receiver, liquidator,
trustee, sequestrator, assignee, síndico, interventor (or similar official) of the Borrower or any Subsidiary or
of any substantial part of its respective Property or Debt or fails to timely and appropriately contest any proceeding or petition described
in (i), (ii) or (iii); (v) the Borrower or any Subsidiary makes a general assignment for the benefit of creditors; (vi) the Borrower
or any Subsidiary admits in writing its inability or otherwise becomes unable to pay its debts generally as they become due; (vii) the
Borrower or any Subsidiary is or becomes subject to judicial or extra-judicial reorganization or to any temporary administration or intervention
by any Authority; or (viii) any other event occurs that under any Applicable Law would have an effect similar to any of those events
listed above.

 

    Annex 1-9
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Intellectual
Property” means all patents, letters patent (including applications, improvements, prolongations, extensions, and rights to
apply therefor), logos, labels, designs, (whether registered or unregistered), copyrights, design rights, trademarks, and service marks
(whether registered or unregistered), utility models, company names, business names, trade names, processes, know-how, confidential information,
trade secrets, formulas, inventions, computer software, programs, and systems (including the benefit of any licenses, permits, consents
or franchises relating to any of the above, and including applications, improvement, prolongations, extensions, and rights to apply therefor),
and other similar rights, and all registrations with respect to any of the foregoing, whether owned, leased or licensed, or otherwise
used by the Borrower or any of its Subsidiaries, and all fees, royalties, or other rights derived therefrom, or incidental thereto, in
any part of the world. Notwithstanding the foregoing, “Intellectual Property” shall not include (i) non-exclusive software
licenses and (ii) non-exclusive licenses that are not material to the operation of the business of the Borrower or any of its Subsidiaries.

 

“Intercreditor
Agreement” means an agreement of that name entered into, or to be entered into, between BlaO and IDB Invest.

 

“Interest
Payment Date” means the 15th day of each April and October of each year.

 

“Interest
Period” means each six (6)-month period beginning on an Interest Payment Date and ending on the next following Interest Payment
Date, except for the first period following each Disbursement for which it shall mean the period beginning on such Disbursement Date
and ending on the next following Interest Payment Date.

 

“Interest
Rate” means the rate of interest payable on the outstanding principal amount of the BlaO Loan from time to time, determined
in accordance with Section 2.13 (BlaO Loan Interest).

 

“Interest
Rate Determination Date” means the second (2nd) Business Day prior to the commencement of each Interest Period; provided,
that the Interest Rate Determination Date for the first Interest Period following each Disbursement shall be the second (2nd) Business
Day prior to the relevant Disbursement Date.

 

“Interest
Reserve Amount” has the meaning provided in Section 2.2.4(i)(a) (Disbursement Procedure).

 

“Interest Reserve
Period” has the meaning provided in Section 2.2.4(i) (Disbursement Procedure).

 

“Internationally
Recognized Sanctions Lists” means sanctions lists maintained by the Office of Foreign Assets Control (OFAC) of the United States
Department of Treasury, the United Kingdom of Great Britain and Northern Ireland, the United Nations and the European Union.

 

“Key
Performance Indicators” means the key performance indicators listed in Schedule 7 (Key Performance Indicators).

 

“Lien”
means any mortgage, pledge, charge, assignment, hypothecation, lien, security interest, title retention, preferential right (arising
by operation of law or otherwise), trust arrangement, right of set-off, counterclaim or banker’s lien, privilege or priority of
any kind having the effect of security, including any designation of loss payees or beneficiaries or any similar arrangement under any
insurance policy.

 

    Annex 1-10
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“List
of Excluded Activities” means the list of activities not financed by BlaO set forth in Schedule 2 (List of Excluded
Activities).

 

“Loan
Final Maturity Date” means the date that occurs on the seventh (7th) anniversary of the Effective Date or, if such date is
not an Interest Payment Date, then the next preceding Interest Payment Date.

 

“Mandatory
Prepayment Event” has the meaning provided in Section 2.4.2 (Mandatory Prepayments).

 

“Market
Disruption Base Rate” means an interest rate per annum equal to (i) the cost of funds of BlaO, determined in accordance with
Section 2.15 (Market Disruption) or (ii) any other rate applicable pursuant to either Section 2.15.2(i) or Section 2.15.2(ii)
as determined by BlaO.

 

“Market
Disruption Event” has the meaning provided in Section 2.15.1 (Market Disruption).

 

“Material
Adverse Effect” means a material adverse effect on: (i) the business, Property, liabilities, operations or condition, financial
or otherwise, of the Borrower and its Subsidiaries taken as a whole; (ii) the ability of the Borrower and its Subsidiaries taken as a
whole to perform its obligations under any Financing Document to which it is a party; (iii) the rights or remedies of BlaO under the
Financing Documents; or (iv) the validity or enforceability of any material provision of any
Financing Document; or (v) the perfection, priority, enforceability or value of the Security.

 

“Merqueo
Brazil” means Merqueo Comércio Varejista e Intermediação de Negócios Ltda., a company organized
and existing under the laws of Brazil.

 

“Merqueo
International” means Merqueo International S.A.S., a simplified stock corporation organized and existing under the laws of
the Borrower’s Country.

 

“Merqueo
Mexico” means Merqueo S.A. de C.V., a company duly incorporated under the laws of Mexico, a company incorporated under the
laws of Mexico.

 

“Mexico”
means the United Mexican States.

 

“Most
Favored Lender Provisions” has the meaning provided in Section 5.1.16 (Most Favored Lender).

 

“Notes”
has the meaning provided in Section 2.17.1 (Initial Notes).

 

“Obligations”
means collectively:

 

		(i)	the
                                            unpaid amount of principal of, and interest and Additional Interest on, the BlaO Loan (including
                                            default interest and ordinary interest accruing after the maturity of the BlaO Loan and after
                                            the filing of any petition in bankruptcy, or the commencement or occurrence of any Insolvency
                                            Event relating to the Borrower); and

 

		(ii)	all
                                            expenses, Costs, fees and other obligations and liabilities of the Borrower under this Agreement
                                            or any other Financing Document to BlaO.

 

“Other
Taxes” has the meaning provided in Section 2.9.1 (Taxes).

 

“Permitted
Liens” means in respect of the Borrower and its Subsidiaries:

 

		(i)	Liens
                                            created under or pursuant to any Security Document;

 

    Annex 1-11
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

		(ii)	any
                                            Lien arising from any tax, assessment or other Lien arising by operation of law while the
                                            indebtedness underlying that Lien is not yet due or, if due, is being contested in good faith
                                            by appropriate proceedings and for the payment of which reserves, bonds, insurance or other
                                            security has been provided in an amount sufficient to promptly pay in full any amounts that
                                            the Borrower or the relevant Subsidiary may be ordered to pay on final determination of any
                                            such proceedings;

 

		(iii)	the
                                            naming of BlaO as loss payee, beneficiary, or additional insured under the Borrower’s
                                            and its Subsidiaries’ insurance policies;

 

		(iv)	the
                                            naming of additional insureds under the Borrower’s and its Subsidiaries’ insurance
                                            policies in the ordinary course of business;

 

		(v)	mechanics’,
                                            materialmens’, construction and other similar Liens arising in the ordinary course
                                            of business that either (a) are not overdue for a period of more than ninety (90) days or
                                            (b) are for amounts being contested in good faith and by appropriate proceedings, so long
                                            as a bond or other security instrument has been posted or other adequate provision for payment
                                            thereof has been provided in such manner and amount as required by the Accounting Principles;

 

		(vi)	Liens,
                                            pledges or deposits under worker’s compensation, unemployment insurance or other social
                                            security legislation;

 

		(vii)	easements,
                                            rights-of-way, restrictions and other similar encumbrances incurred in the ordinary course
                                            of business and encumbrances consisting of zoning restrictions, licenses, restrictions on
                                            the use of property or minor imperfections in title that could not reasonably be expected
                                            to have a Material Adverse Effect; and

 

		(viii)	any
                                            Lien securing a Debt on any asset of the Borrower in existence on the date of this Agreement
                                            which Lien and Debt are described in Schedule 4 (Permitted Liens) or any Lien
                                            securing an extension, renewal or refinancing of such Debt; provided that (a) such
                                            Lien is created over the assets that secured such Debt and (b) the principal amount of Debt
                                            secured by such Lien prior to such extension, renewal or refinancing is not increased, other
                                            than with respect to reasonable costs, fees and expenses incidental to such extension, renewal,
                                            or refinancing.

 

“Person”
means any individual or any company, partnership, joint venture, firm, corporation, voluntary association, trust, enterprise, unincorporated
organization or other corporate body or any Authority or any other entity whether acting in an individual, fiduciary or other capacity,
including that Person’s successors and permitted assigns.

 

“PIK
Fee” has the meaning provided in Section 2.12.1(ii) (Fees).

 

“Process
Agent” has the meaning provided in Section 7.10.4 (Applicable Law and Jurisdiction).

 

    Annex 1-12
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Prohibited
Practice” means any of the following: (i) impairing or harming, or threatening to impair or harm, directly or indirectly, any
party or the property of the party to influence improperly the actions of a party (a “Coercive Practice”); (ii) an
arrangement between two or more parties designed to achieve an improper purpose, including influencing improperly the actions of another
party (a “Collusive Practice”); (iii) offering, giving, receiving, or soliciting, directly or indirectly, anything
of value to influence improperly the actions of another party (a “Corrupt Practice”); (iv) any action or omission,
including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party in order to obtain a financial
or other benefit or avoid an obligation (a “Fraudulent Practice”); (v) (a) destroying, falsifying, altering or concealing
of evidence material to an IDB Group investigation or an investigation by BlaO, or making false statements to investigators with the
intent to impede an IDB Group investigation or BlaO investigation; (b) threatening, harassing or intimidating any party to prevent it
from disclosing its knowledge of matters relevant to an IDB Group investigation or BlaO investigation or from pursuing the investigation;
or (c) acts intended to impede the exercise of the IDB Group’s or BlaO’s contractual rights of audit or inspection or access
to information (each an “Obstructive Practice”); and (vi) the use of IDB Group or BlaO’s financing or resources
for an improper or unauthorized purpose, committed either intentionally or through reckless disregard (a “Misappropriation”).

 

“Property”
means any right or interest in or to assets or property of any kind whatsoever, whether real, personal or mixed and whether tangible
or intangible.

 

“Rate
Setting Period” has the meaning provided in Section 2.15.2(ii) (Market Disruption).

 

“Receipt Account”
has the meaning provided in Section 2.6.1 (Currency and Place of Payment).

 

“Relevant
Authorization” means each Authorization that is or may be at any time necessary under Applicable Law: (a) for making the BlaO
Loan and each Disbursement; (b) material for the Borrower and each of its Subsidiaries to conduct its business as it is contemplated
to be carried on; (c) for the purposes of the BlaO Loan to be carried out in accordance with the Financing Documents; (d) in connection
with the execution, delivery, validity and enforceability of the Financing Documents and the performance by each party thereto of its
obligations thereunder; (e) for the enforcement by BlaO of its rights and remedies under the Financing Documents; (f) for the remittance
to BlaO or its assigns in Dollars of all monies payable under or with respect to the Financing Documents; and (g) for the BlaO Loan and
the Borrower and its Subsidiaries to comply with Applicable Law and Annex 2 (Environmental and Social Provisions).

 

“Relevant
Governmental Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed
or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York or any successor thereto.

 

“Restricted
Payment” means (i) any dividend or distribution (whether in cash, Property or obligations) on, any other payment or deposit
made on account of, any declaration of any dividend, distribution or similar payment in respect of, and the purchase, redemption, retirement
or other acquisition of, any portion of the Borrower’s Share Capital (other than in connection with IDB Invest’s exercise
of the put option under the IDB Invest Put Option Agreement) or Equity Rights in respect of the Borrower, including any dividends, distributions
or other payments made or to be made by the Borrower to its Shareholders, Affiliates, or other Persons for or on account of capital reductions,
repurchases or redemptions of outstanding stock, options or warrants, and investments in, and capital contributions, loans and advances
to, the Borrower, and other similar payments in respect of Equity Rights; (ii) any payment, purchase, or retirement or other acquisition
of any debt (whether or not subordinated), loan, account or other financial obligation owed to any Shareholder or Affiliate thereof (including
any deposit or similar payment made to secure any such debt, loan, account or financial obligation); and (iii) any payment of development,
management or operation fees to any Shareholder or Affiliate of the Borrower, except as set forth in the Founders’ employment or
services agreements.

 

“Secured
Property” means all Property, and the products and proceeds thereof, from time to time subject, or purported to be subject,
to the Security.

 

    Annex 1-13
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“Security”
means the first priority Liens created, or purported to be created, over all of the shares of each Subsidiary under the Security Documents
to secure all of the Obligations and the corresponding obligations owed to IDB Invest in respect of the IDB Invest Loan.

 

“Security
Documents” means: (i) all agreements relating to the Security; and (ii) all other notices, consents, acknowledgements and documents
necessary or advisable to perfect the security interest of the Senior Lenders in the Secured Property, as each may be amended, modified,
supplemented, renewed or restated.

 

“Senior
Lenders” means BlaO, IDB Invest and their successors and assigns.

 

“Senior Loans” means the BlaO Loan and
the IDB Invest Loan.

 

“Share
Capital” means, as to any Person (other than an individual), all shares of capital stock of any class or other ownership interests
of any kind, however called, in such Person, and any and all warrants, subscription bonus, convertible debentures or debt, options or
other rights to purchase, subscribe or otherwise acquire title to any of the foregoing.

 

“Shareholder”
means any Person that owns Share Capital of the Borrower.

 

“SOFR”
means the secured overnight financing rate published by the SOFR Administrator on the SOFR Administrator’s website, currently at
http://www.newyorkfed.org, or any successor source identified by the SOFR Administrator from time to time.

 

“SOFR
Administrator” means the Federal Reserve Bank of New York, as administrator of SOFR (or any successor administrator thereof
from time to time).

 

“SPAC
Transaction” means a transaction between or among the Shareholders and Rose Hill Acquisition Corporation (NASDAQ Ticker Symbol:
ROSEU), a special purpose acquisition company (a “SPAC”), which results in the ownership of the Borrower’s Share
Capital being held directly or indirectly by such SPAC and such SPAC: (i) continues to be subject to reporting requirements under the
U.S. Securities Exchange Act of 1934; and (ii) continues to have its Share Capital listed and publicly traded on the NASDAQ Stock Exchange.

 

“Subsidiary”
means, with respect to any Person, any entity: (i) over fifty percent (50%) of whose Share Capital is owned, directly or indirectly,
by that Person; (ii) for which that Person may nominate or appoint a majority of the members of the Board of Directors; or (iii) that
is otherwise Controlled by that Person.

 

“Tax
Returns” means all returns, declarations, reports, estimates, information returns, statements and other documents of, relating
to, or required to be filed with any Authority in respect of Taxes.

 

“Taxes”
means all present and future taxes, charges, fees, duties, contributions, withholding obligations or other assessments of whatsoever
nature levied by any Authority, together with any interest, penalties, additions to tax or other liabilities imposed thereon by any Authority.

 

“Term
SOFR” means the forward-looking term rate based on SOFR administered by the Term SOFR Administrator.

 

“Term
SOFR Administrator” means CME Group Benchmark Administration Limited (or any successor administrator of a forward-looking term
rate based on SOFR selected by BlaO from time to time in its sole discretion).

 

“Transaction
Taxes” has the meaning provided in Section 2.9 (Taxes).

 

“Unauthorized
Share Transaction” means any transaction affecting or changing the Share Capital held or to be acquired by any Person in the
Borrower (whether directly or indirectly, through the ownership by such Person of Share Capital in any other Person) if (i) (a) such
transaction or such Person violates, or would result in the Borrower violating, the Applicable Laws of the Borrower’s Country,
or (b) such Person is included in the Internationally Recognized Sanctions Lists or in the IDB Group List of Sanctioned Firms and Individuals
and, (ii) such Person holds or would as a result of such transaction hold in aggregate in excess of five percent (5%) of the total Share
Capital of the Borrower.

 

    Annex 1-14
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“U.S.
Government Securities Business Day” means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the U.S.
Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire
day for purposes of trading in United States government securities.

 

“Warehouse
Leases” means the warehouse leases listed in Schedule 5 (Warehouse Leases).

 

Financial
Definitions

 

“Adjusted
EBITDA” means, for any period of determination and with respect to operations in Colombia, Mexico and Brazil, whether conducted
directly or indirectly through the Guarantors or any other Subsidiaries of the Borrower, determined on a Consolidated Basis (but excluding
operations in any other jurisdictions) in accordance with the Accounting Principles, the sum (determined without duplication) of: (i) 
the Consolidated Operating Income for such period plus (ii) depreciation and amortization to the extent deducted when determining
Consolidated Operating Income for such period plus/minus (iii) other applicable items, such as other Non-Cash Items not previously
accounted for, if any, to the extent deducted/added when determining Consolidated Operating Income for such period.

 

“Capital
Contributions” means, as of any Determination Date and in respect of the Determination Period ending on such Determination
Date, any increase of debt and/or equity during such Determination Period of the Borrower and its Subsidiaries under the Accounting Principles
on a Consolidated Basis.

 

“Capitalized
Research & Development” means, as of any Determination Date and in respect of the Determination Period ending on such Determination
Date, any research and development costs capitalized during such Determination Period of the Borrower and its Subsidiaries under the
Accounting Principles on a Consolidated Basis.

 

“Cash
Flow from Financing Activities” means, as of any Determination Date and in respect of the Determination Period ending on such
Determination Date, the amount of cash flow from financing activities during such Determination Period of the Borrower and its Subsidiaries
under the Accounting Principles on a Consolidated Basis.

 

“Cash
Held at the Beginning of the Period” means, in respect of any Determination Period, the aggregate amount of cash and cash equivalents
held by the Borrower and its Subsidiaries on a Consolidated Basis on the first day of the relevant Determination Period.

 

“Cash
Flow Available for Debt Service” means, as of any Determination Date and in respect of the Determination Period ending on such
Determination Date, the aggregate on a Consolidated Basis of the Borrower’s and its Subsidiaries’ (determined without duplication):
(i) Net Cash Flow from Operations, plus (ii) Capitalized Research & Development,
plus (iii) interest from the Right Use of Assets, plus (iv) interest on Debt, including any Additional Interest and fees,
plus (v) any financial expense to the extent it has been deducted in determining Net Cash flow from Operations, minus (vi)
Cash Flow from Financing Activities, plus (vii) Capital Contributions, minus (viii) Dividends, minus (ix) any other
financial outflows other than Debt related amortization, interest and fees.

 

“Consolidated
or Consolidated Basis” means, with respect to any Financial Statements to be provided, or any financial calculation
or determination to be made, under or for purposes of this Agreement or any other Financing Document, the method referred to in Section
1.4 (Financial Calculations).

 

“Consolidated
EBITDA” means, as of any Determination Date and in respect of the Determination Period ending on such Determination Date, for
the Borrower and its Subsidiaries determined on a Consolidated Basis in accordance with the Accounting Principles, the sum (determined
without duplication) of: (i) the Consolidated Operating Income for such Determination Period plus (ii) depreciation and amortization
to the extent deducted when determining Consolidated Operating Income for such Determination Period plus/minus (iii) other applicable
items, such as other Non-Cash Items not previously accounted for, if any, to the extent deducted/added when determining Consolidated
Operating Income for such Determination Period.

 

“Consolidated
Operating Income” means, as of any Determination Date and in respect of any period of determination ending on such Determination
Date, for the Borrower and its Subsidiaries determined on a Consolidated Basis in accordance with the Accounting Principles, the sum
(determined without duplication) of: (i) revenues, minus (ii) the cost of goods sold, minus (iii) general, administrative,
and sale expenses, minus (iv) depreciation and amortization.

 

“Debt
Service” means, as of any Determination Date and in respect of the Determination Period ending on such Determination Date,
for the Borrower and its Subsidiaries determined on a Consolidated Basis in accordance with the Accounting Principles, the sum (determined
without duplication) of: (i) all scheduled payments (whether or not actually paid) falling due on account of principal of Debt and interest
and other charges on Debt, plus (ii) any payment made or required to be made to any debt service account under the terms of any
agreement providing for Debt plus (iii) all payments (whether or not actually paid) falling due on account of operating leases,
including interest and any other fees and charges related to such operating leases.

 

“Determination
Date” means March 31, June 30, September 30, and December 31, of each year.

 

“Determination
Period” means each period of four Financial Quarters ending on the relevant Determination Date.

 

“Dividends”
means, as of any Determination Date and in respect of the Determination Period ending on such Determination Date, the aggregate amount
of Restricted Payments made by the Borrower during such Determination Period (disregarding, for this purpose, the parenthetical relating
to the IDB Invest Put Option Agreement in clause (i) of the definition of Restricted Payments herein).

 

“Financial
Statements” means, with respect to any Person, as of any relevant date and period, such Person’s balance sheet, income
statement, cash flow statement, statement of sources and uses of funds, statement showing changes in equity and any exhibits and notes
thereto, which shall be prepared (i) in respect of the Borrower, in Colombian Pesos on a Consolidated Basis and (ii) in respect of each
Subsidiary, in its respective local currency, all prepared on a consistent basis in accordance with the Accounting Principles.

 

    Annex 1-15
BlaO Loan Agreement

     

    

 

CONFIDENTIAL

 

“IRR”
means the internal rate of return on the BlaO Loan or portion thereof being prepaid, expressed as an annualized rate based on a three
hundred sixty five (365)-day period used to discount each cash flow in Dollars in respect of the BlaO Loan or portion thereof being prepaid,
calculated from the date or dates of such cash flows, and taking into account the amounts of the following, such that the present value
of the aggregate of such cash flows equals zero:

 

		(i)	each
                                            Disbursement of the BlaO Loan;

 

		(ii)	all
                                            payments of interest, Additional Interest and fees made hereunder; and

 

		(iii)	all
                                            principal payments made in respect of the BlaO Loan.

 

For
avoidance of doubt, the IRR shall be the output value obtained using the ‘XIRR’ function of Microsoft Excel in which: (a)
the cash flows and dates thereof set forth in the immediately preceding sentence shall be the inputs in the worksheet; and (b) the net
cash inflows of interest, Additional Interest, fees and principal payments to BlaO shall be positive inputs and all Disbursements of
the BlaO Loan shall be negative inputs in the worksheet.

 

“Maximum
Net Debt to Consolidated EBITDA Ratio” means, as of any Determination Date, the ratio obtained by dividing (i) the outstanding
Net Financial Debt as of such Determination Date by (ii) the aggregate amount of Consolidated EBITDA for the Determination Period ending
on such Determination Date.

 

“Minimum
Historical DSCR” means, as of any Determination Date, the ratio obtained by dividing (i) the sum (determined without duplication)
of (a) the Cash Flow Available for Debt Service for the Determination Period ending on such Determination Date, plus (b) Cash
Held at the Beginning of the Period for such Determination Period, by (ii) the Debt Service for such Determination Period.

 

“Minimum
Prospective DSCR” means, as of any Determination Date, the ratio obtained by dividing (i) the sum (determined without duplication)
of (a) the Cash Flow Available for Debt Service for the Determination Period ending on such Determination Date, plus (b) Cash
Held at the Beginning of the Period for such Determination Period, by (ii) the Projected Debt Service for the Relevant Period immediately
following such Determination Date.

 

“Net
Cash Flow from Operations” means, for any Determination Period, the net cash flows from operations of the Borrower and its
Subsidiaries determined on a Consolidated Basis in accordance with the Accounting Principles.

 

“Net
Financial Debt” means, as of any Determination Date, (i) the sum (determined without duplication) of (a) the Borrower’s
and its Subsidiaries’ Financial Debt plus (b) all remaining payments owing in respect of operating leases, minus (ii)
cash and marketable securities, determined on a Consolidated Basis in accordance with the Accounting Principles.

 

“Non-Cash
Items” means, with respect to any Person for any period, the net aggregate amount (which may be a positive or negative number)
of all non-cash expenses and non-cash credits that have been subtracted or, as the case may be, added in calculating the net income of
such Person during that period, including depreciation, amortization, deferred taxes, provisions for severance pay of staff and workers.

 

“Projected Debt Service” means, for any Relevant Period,
for the Borrower and its Subsidiaries determined on a Consolidated Basis, the sum (determined without duplication) of: (i) all scheduled
payments projected to fall due on account of principal of Debt and interest and other charges on Debt, plus (ii) any payment projected
to be made or required to be made to any debt service account under the terms of any agreement providing for the Debt during the Relevant
Period; provided, that, for the computation of interest payable during any period for which the applicable rate is not yet determined,
that interest shall be computed at the rate in effect on the relevant date of calculation plus (iii) all scheduled payments projected
to fall due on account of operating leases during such Relevant Period, including interest and any other fees and charges related to
such operating leases.

 

“Relevant
Period” means each period of four Financial Quarters immediately following a Determination Date.

 

“Right
Use of Assets” means, as of any Determination Date, any right use of assets reflected on the Consolidated balance sheet of
the Borrower and its Subsidiaries.

 

    Annex 1-16
BlaO Loan Agreement

     

    

 

Execution
Version

 

CONFIDENTIAL

 

ANNEX
2

 

ENVIRONMENTAL
AND SOCIAL PROVISIONS

 

Section
1. E&S Definitions.

 

Capitalized
terms used but not defined in this Annex 2 (Environmental and Social Provisions) shall have the meanings provided in Annex
1 (Definitions). The following terms are used in this Annex 2 and throughout this Agreement and all exhibits, schedules,
plans, reports, and certifications presented and approved thereunder with the following meanings:

 

“Corrective
Action Plan” means a corrective or mitigation plan, including a cost breakdown, allocation of responsibilities, and an implementation
schedule, which, once initiated, will enable the Borrower to correct and remediate the damage and adverse effects resulting from any
failure to comply with the Environmental and Social Action Plan, the Sustainability Policy, the Environmental and Social Standards and
Guidelines, or the Environmental and Social Legislation, or to correct or mitigate the adverse effects of any Serious Incident.

 

“Environmental
and Social Action Plan” means the plan prepared by the Borrower in accordance with Annex 2A (Environmental and Social
Action Plan) attached to this Annex 2, which shall indicate the necessary actions, including the allocation of responsibilities and
implementation schedule, for the purpose of ensuring that the design, operation, and maintenance of all the Borrower’s facilities,
plants, and equipment meet and maintain compliance with the Environmental and Social Standards and Guidelines, the Environmental and
Social Legislation and the Sustainability Policy.

 

“Environmental
and Social Legislation” means all applicable statutes, laws, regulations, decrees, resolutions, codes, orders, plans, court
decrees, and applicable judicial or administrative decisions or interpretations issued at the international, national, state, municipal,
or sector level that govern or make reference to Environmental and Social Issues.

 

“Environmental
and Social Monitoring Report” means the true, accurate and complete report on compliance with the environmental guidelines
established in the Environmental and Social Action Plan, confirming compliance with said guidelines or detailing the noncompliance thereof,
together with the remedial action taken to ensure compliance with said Environmental and Social Action Plan.

 

“Environmental
and Social Standards and Guidelines” means sector-specific guidelines and performance standards that contain best environmental
and social practices to be implemented by the company in the design, operation, and maintenance of all its facilities, plants, and equipment,
pursuant to the Sustainability Policy and other guiding regulations and documents listed in the Environmental and Social Action Plan.

 

“Serious
Incident” means an event of accident, death, spillage of hazardous substances, explosions, fire, environmental or social claims
or suits, significant complaints from the public or environmental authorities, or significant personal injury, among others.

 

“Sustainability
Policy” means the IDB Invest Environmental and Social Sustainability Policy (document CII/GP-16-15), available at: https://idbinvest.org/sites/default/files/2020-05/idb_invest_sustainability_policy_2020_EN.pdf.

 

    Annex 2-1
BlaO Loan Agreement

     

    

 

Section
2. E&S Representations and Warranties.

 

		2.1.	Environmental
                                            and Social Considerations. The Borrower declares that it and each of the Guarantors is
                                            in substantial compliance with the Environmental and Social Legislation, the Sustainability
                                            Policy and the applicable Environmental and Social Standards and Guidelines, with the exception
                                            of any action specifically noted in the Environmental and Social Action Plan as still pending
                                            with respect to achieving said substantial compliance.

 

Section
3. E&S Conditions Precedent to First Disbursement.

 

[Intentionally
Omitted.]

 

Section
4. E&S Conditions Precedent to All Disbursements.

 

[Intentionally
Omitted.]

 

Section
5. E&S Affirmative Covenants.

 

		5.1.	Unless
                                            previously authorized in writing by BlaO, the Borrower shall, and shall cause each of the
                                            Guarantors to, comply with the following obligations set forth below:

 

		(i)	Due
                                            Diligence and Use of Loan Proceeds. Conduct its business with due diligence, in an efficient
                                            and environmentally responsible manner, adhering fully to the customary practices in its
                                            area of business and ensuring that all its operations are carried out in accordance with
                                            market conditions. Execute the Environmental and Social Action Plan;

 

		(ii)	Annual
                                            Reporting. Within no more than forty five (45) days from the close of each Financial
                                            Year, provide BlaO an Environmental and Social Monitoring Report;

 

		(iii)	Laws,
                                            Rules, and Regulations. Conduct all its activities in accordance with all national, provincial,
                                            and municipal laws, rules, and regulations applicable to said activities, including any applicable
                                            Environmental and Social Legislation; and

 

		(iv)	Licenses,
                                            Approvals or Permits. Maintain in force all licenses, approvals, and permits necessary
                                            for its business and operations, in general, including, but not limited to, those issued
                                            by any Governmental Authority and required by any Environmental and Social Legislation. Comply
                                            with and observe all conditions and restrictions contained in or imposed by any such licenses,
                                            approvals, or permits.

 

		5.2.	Environmental
                                            and Social Considerations. Design, build, operate, and maintain all of the Borrower’s
                                            facilities, plants, and equipment in accordance with the requirements set forth in the Environmental
                                            and Social Action Plan, the Environmental and Social Legislation, the Environmental and Social
                                            Standards and Guidelines, and the Sustainability Policy. In the event that the Borrower or
                                            any Guarantor detects:

 

		(i)	any
                                            noncompliance with the Environmental and Social Action Plan, the Environmental and Social
                                            Legislation, the Environmental and Social Standards and Guidelines, and/or the Sustainability
                                            Policy; or

 

    Annex 2-2
BlaO Loan Agreement

     

    

 

		(ii)	any
                                            Serious Incident, the Borrower shall:

 

		(a)	notify
                                            BlaO within ten (10) Business Days from occurrence in the event of any such noncompliance,
                                            or within seventy-two (72) hours in the event of a Serious Incident, providing a reasonably
                                            detailed written description of such noncompliance or Serious Incident, including, but not
                                            limited to an account of (i) fatalities or serious injuries to personnel, and/or (ii) releases
                                            of hazardous substances, and/or (iii) unplanned releases, and/or (iv) explosions or fires;

 

		(b)	shall
                                            engage, diligently and at its own expense, the services of a qualified professional satisfactory
                                            to BlaO, to investigate the noncompliance or Serious Incident and prepare a written report
                                            for BlaO describing the event, in the understanding that such report shall include a reasonable
                                            description of the event, detailing its extent, magnitude and impact; and

 

		(c)	shall
                                            take, diligently and at its own expense, all the steps necessary to implement the pertinent
                                            Corrective Action Plan in a form and substance satisfactory to BlaO.

 

		5.3.	Monitoring
                                            and Inspection Visits. At the request of BlaO, allow BlaO or the person it designates
                                            to visit and inspect the Borrower’s and each Guarantor’s properties; conduct
                                            appraisals; examine the applicable business records, accounting books, and tax returns; and
                                            request from the Borrower’s and each Guarantor’s officials information about
                                            the Borrower’s and each Guarantor’s activities, assets, operational activities,
                                            financial situation, operating results, outlook, and the state of its compliance with the
                                            requirements pertaining to the Environmental and Social Issues and the implementation of
                                            the Environmental and Social Action Plan, at appropriate times and with appropriate frequency
                                            (at least once a year).

 

Section
6. E&S Negative Covenants.

 

[Intentionally
Omitted.]

 

Section
7. Events of Default.

 

		7.1.	The
                                            Borrower fails to implement or comply with the Environmental and Social Action Plan and fails
                                            to remedy said noncompliance within thirty (30) days from BlaO’s corresponding written
                                            notice to the Borrower.

  

 

Annex 2-3

BlaO Loan AgreementExhibit 10.1

 

EXECUTION
COPY

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT
(this “Agreement”), made effective as of the 1st day of January, 2023 (the “Effective Date”),
is entered into by and between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Jeffrey
W. Albers (the “Consultant”).

 

INTRODUCTION

 

WHEREAS,
the Consultant is a member of the Board of Directors (the “Board”) of the Company and also served as a part time employee
of the Company with the title Executive Chairman until December 31, 2022 pursuant to an Amended and Restated Employment Agreement
effective as of April 4, 2022 by and between the Company and the Consultant (the “Employment Agreement”) that
expired on December 31, 2022 (the “Employment Termination Date”) by its terms; and

 

WHEREAS,
the Consultant’s employment with the Company ended on the Employment Termination Date; and

 

WHEREAS,
the Consultant continues to serve as Chairman of the Board; and

 

WHEREAS,
the Consultant is a highly experienced biotechnology executive with prior experience developing and leading commercial teams and launching
products; and

 

WHEREAS,
the Company and the Consultant desire to establish the terms and conditions under which the Consultant shall provide advisory services
to the Company;

 

NOW,
THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows:

 

1.             Services.

 

1.1           Consulting
Services. In the role of senior advisor to the Company, the Consultant agrees to provide such advisory services to the Company (including
without limitation through meetings with members of its senior management) as described in more detail in Exhibit A hereto,
which are anticipated not to exceed sixteen (16) hours per month on average (“Consulting Services”). The total number
of hours of services to be provided by the Consultant during the Consultation Period (as defined below) shall not exceed twenty percent
(20%) of the total number of hours of services that the Consultant provided in a thirty six-month period as an employee of the Company
immediately prior to the Effective Date.

 

1.2           Performance.
The Consultant agrees to provide the Consulting Services to the Company in accordance with all applicable laws and regulations and the
highest professional standards. The Consultant represents and warrants that he has not been, and is not under consideration to be: (a) debarred
from providing services pursuant to Section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. §335a; (b) excluded,
debarred or suspended from, or otherwise ineligible to participate in, any federal or state health care program or federal procurement
or non-procurement programs (as that term is defined in 42 U.S.C. §1320a-7b(f)); (c) disqualified by any government or regulatory
agencies from performing specific services, and is not subject to a pending disqualification proceeding; or (d) convicted of a criminal
offense related to the provision of health care items or services, or under investigation or subject to any such action that is pending.

 

     

     

    

 

2.             Term.
This Agreement shall commence on the Effective Date and shall continue until such date on which the Consultant’s service is terminated
in accordance with the provisions of Section 4 (such period, the “Consultation Period”).

 

3.             Compensation.

 

3.1           Consulting
Fee. During the Consultation Period, the Company shall pay to the Consultant a consulting fee in the aggregate amount of US$9,583.33
per month (US$115,000.00 on an annual basis) for Consulting Services, which shall be payable quarterly in arrears on the last day of each
calendar quarter. Payment for any partial month of service during the Consultation Period shall be prorated.

 

3.2           Expenses.
The Company shall reimburse the Consultant for all pre-approved, reasonable and necessary documented out-of-pocket expenses actually incurred
or paid by the Consultant in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement,
including Consultant’s travel and lodging expenses, upon presentation by the Consultant of a reasonably detailed expense report
plus documentation, expense statements, vouchers and/or such other supporting information as the Company may reasonably request, all subject
to the Company’s travel and expense policy. The Consultant shall promptly submit to the Company itemized monthly statements of such
expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within thirty (30)
days after receipt thereof.

 

3.3           Benefits.
To the extent the Consultant was participating in any of the Company’s group medical, dental and vision benefits as of the Employment
Termination Date, any further right of the Consultant and the Consultant’s eligible dependents to continue group medical, dental
and vision insurance coverage will be subject to the Consultant’s timely election of COBRA, and the Company may continue group medical,
dental and vision insurance coverage for the Consultant and any of the Consultant’s eligible dependents under the Company’s
applicable group health plans at the Consultant’s sole expense, to the extent the Consultant and such dependents remain eligible.
The Consultant’s participation in the Company’s other benefits programs (if any) will end on the Employment Termination Date
or thereafter in connection with the applicable benefits program. Notwithstanding the foregoing, the Consultant will remain eligible to
receive prorated 2022 incentive compensation (the “Prorated 2022 Bonus”) for the period beginning on January 1,
2022 and ending on April 3, 2022 (inclusive) in connection with his services as President and Chief Executive Officer of the Company
during such period, as determined by the Board or the Compensation Committee thereof based on his target incentive compensation equal
to 70% of his annual base salary as in effect during such period (and the Board or the Compensation Committee thereof shall weigh its
bonus determination 100% on Company performance), provided that the Consultant remains a member of the Board on the day such incentive
compensation is paid, which in any event will be no later than March 15, 2023. The Prorated 2022 Bonus will be subject to applicable
tax withholdings. For the avoidance of doubt, other than the Prorated 2022 Bonus, the Consultant is not eligible for any incentive compensation
from the Company under the Employment Agreement or otherwise.

 

    	 	- 2 -	 

     

    

 

3.4           Taxes.
The Consultant acknowledges and agrees that the Consultant is obligated to report as income all compensation received by the Consultant
pursuant to this Agreement, and the Consultant agrees to and acknowledge the obligation to pay all taxes including without limitation
all federal and state income tax, social security taxes and unemployment, disability insurance and workers’ compensation applicable
to the Consultant. The Consultant shall indemnify and hold the Company harmless from any liability for, or assessment of, any such taxes
imposed on the Company by relevant taxing authorities.

 

4.             Term
and Termination. The term of this Agreement shall commence on the Effective Date and end on December 31, 2023 unless otherwise
mutually agreed in writing by the parties. This Agreement may be terminated by either the Company or the Consultant upon not less than
ninety (90) days’ prior written notice to the other party; provided, however, that either party may terminate this
Agreement immediately upon written notice to the other party in the event such other party has materially breached this Agreement. In
the event of the expiration or any termination of this Agreement, the Consultant shall be entitled to (i) payment of consulting fees
for the period ending as of the effective date of such expiration or termination and (ii) reimbursement for out-of-pocket expenses
actually incurred or paid by the Consultant hereunder in accordance with Section 3.2 prior to the effective date of such expiration
or termination.

 

5.             Cooperation.
The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant
to perform his obligations hereunder. The Consultant shall cooperate with the Company’s personnel, shall not interfere with the
conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the
safety of persons and property.

 

6.             Proprietary
Information, Inventions, and Non-Compete.

 

6.1           Proprietary
Information.

 

(a)           The
Consultant acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his service
to the Company he will have access to and contact with Proprietary Information (as defined below). The Consultant shall not disclose any
Proprietary Information to any person or entity other than employees, officers, directors, lawyers, accountants and consultants of the
Company or use the same for any purposes (other than in the performance of his duties as a consultant of the Company) without prior written
approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has
become public knowledge without fault by the Consultant.

 

(b)           For
purposes of this Agreement, “Proprietary Information” shall mean, by way of illustration and not limitation, all information,
whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned,
possessed or used by the Company, concerning the Company's business, business relationships or financial affairs, including, without limitation,
any Invention, formula, vendor information, customer information, trade secrets, process, research, reports, technical or research data,
clinical data and timelines, know-how, technology, products and product candidates, processes, methods, techniques, formulas, compounds,
projects, developments, marketing or business plan, forecast, unpublished financial statement, budgets and long range plans, financing
and business development plans and discussions, licenses, price, costs, supplier or personnel information, or employee list and confidential
information entrusted to the Company by third parties (e.g., existing or potential collaborative partners, licensees, licensors, contract
manufacturing organizations or other vendors) under confidentiality and nonuse obligations that is communicated to, learned of, developed
or otherwise acquired by the Consultant in (i) the course of his prior service as a director of the Company or (ii) in performing
his duties as a consultant of the Company hereunder.

 

    	 	- 3 -	 

     

    

 

(c)           The
Consultant’s obligations under this Section 6.1 shall not apply to any portion of Proprietary Information that Consultant
can demonstrate, by competent proof: (i) is or becomes known to the general public under circumstances involving no breach by the
Consultant or others of the terms of this Section 6.1, (ii) is generally disclosed to third parties by the Company without
restriction on such third parties, or (iii) is approved for release by prior written authorization of an officer of the Company.

 

(d)           The
Consultant agrees that all files, documents, letters, memoranda, reports, records, data sketches, drawings, models, laboratory notebooks,
other written, photographic, or other tangible material containing Proprietary Information, whether created by the Consultant or others,
which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant only
in the performance of his duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of
the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession
of the Consultant shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) the termination
of this Agreement. After such delivery, the Consultant shall not retain any such materials or copies thereof or any such tangible property.

 

(e)           The
Consultant agrees that his obligation not to disclose or to use information and materials of the types set forth in paragraphs (b) and
(d) above, and his obligation to return materials and tangible property set forth in paragraph (d) above extends to such types
of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may
have disclosed or entrusted the same to the Company or to the Consultant.

 

(f)            The
Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government,
or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under
such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions
that are known to him and to take all action necessary to discharge the obligations of the Company under such agreements.

 

    	 	- 4 -	 

     

    

 

(g)           Pursuant
to the federal Defend Trade Secrets Act of 2016, the Consultant shall not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected
violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. Further, nothing in this Agreement shall be interpreted or applied to prohibit the Consultant from making any good faith report
to any governmental agency or other governmental entity concerning any acts or omissions that the Consultant believes to constitute a
possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable
federal or state law or regulation.

 

(h)           Consultant
acknowledges that he is aware that United States and other applicable securities laws prohibit any person who has material, non-public
information about a company from purchasing or selling securities of such company or from communicating such information to any person
under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities.

 

6.2           Inventions.

 

(a)           All
inventions, creations, discoveries, data, developments, technology, designs, innovations, improvements, ideas, concepts, designs, processes,
formulations, products, works of authorship, databases, trade secrets, know-how, information, documentation, reports, research, creations
and other products (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created,
written, designed or developed by the Consultant, solely or jointly with others or under his direction and whether during normal business
hours or otherwise, (i) during the Consultation Period if made, conceived, reduced to practice, created, written, designed or developed
in the course of Consultant’s performance of duties pursuant to this Agreement or (ii) during or after the Consultation Period
if resulting or directly derived from Proprietary Information (collectively under clauses (i) and (ii), “Inventions”),
shall be the sole property of the Company. For purposes of the copyright laws of the United States, Inventions will constitute “works
made for hire,” except to the extent such Work Product cannot by law be “works made for hire”. The Consultant represents
and warrants that the Consultant has and will have the right to transfer and assign to the Company ownership of all Inventions. The Consultant
hereby assigns and transfers and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company
all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights
and applications therefor, in the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney
to execute, file, prosecute and protect the same before any government agency, court or authority.

 

(b)           Upon
the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments, documents and other
instruments as may be necessary or desirable to (i) fully and completely assign all Inventions to the Company, (ii) confirm
the Company’s rights as outlined in this Section 6.2 and (iii) assist the Company in applying for, obtaining and
enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. In the
event that the Consultant should fail or refuse to execute such documents within a reasonable time, the Consultant appoints the Company
as attorney to execute and deliver any such documents on the Consultant’s behalf. The Consultant also hereby waives all claims to
moral rights in any Inventions.

 

    	 	- 5 -	 

     

    

 

(c)           The
Consultant shall promptly disclose to the Company all Inventions and shall maintain adequate and current written records (in the form
of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice
of any Invention. Such written records shall be available to and remain the sole property of the Company at all times.

 

6.3           Non-Compete.
For the longer of (a) the Consultation Period and (b) the 12-month period under Section 8 of the Non-Solicitation, Non-Competition,
Confidentiality and Assignment Agreement, dated as of July 21, 2014 by and between the Company and the Consultant (the “Restrictive
Covenants Agreement”), the Consultant shall not directly or indirectly, whether as owner, partner, shareholder, director, manager,
consultant, agent, employee, co-venturer or otherwise, engage or otherwise participate in any business that (i) researches, develops,
manufactures or markets inhibitors of kinases (including variants thereof) for those kinases in which the Company or its affiliates has
or is contemplating research, development, manufacturing or marketing activities, or (ii) researches, develops, manufactures or markets
any products, or performs any services, that are competitive with the products or services of the Company, or products or services that
the Company or its affiliates has under development or that are the subject of active planning by the Company’s senior management
at any time during the Consultation Period; provided, however, that nothing in this Section 6.3 shall prohibit
an investment in publicly traded stock of a company representing less than one percent of the stock of such company.

 

7.             Other
Agreements. The Consultant represents that his performance of all of the terms of this Agreement do not and will not conflict with
or breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or non-competition
agreement). The Consultant agrees not to disclose to the Company, use or induce the Company to use any trade secrets or other confidential
information of any other person, firm, corporation, institution or other third party in connection with any of the Consulting Services.
If the Consultant is an employee of a company or institution, the Consultant represents and warrants that the Consultant is permitted
to enter into this Agreement pursuant to such company’s or institution’s policies concerning professional consulting and additional
workload. The Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third
party in performing the Consulting Services, nor take any other action that would result in a third party asserting ownership of, or other
rights in, any Invention (as defined in Section 6), unless agreed upon in writing in advance by the Company.

 

8.             Non-Exclusivity.
The Consultant retains the right to be employed or engaged by other companies and to contract with other companies or entities for his
consulting services without restriction other than the Consultant’s compliance with his obligations hereunder, including without
limitation his obligations under Section 6.

 

    	 	- 6 -	 

     

    

 

9.             Remedies.
The Consultant acknowledges that any breach of the provisions of this Agreement shall result in serious and irreparable injury to the
Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition
to any other remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Consultant
and to seek and obtain both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving
actual damages or posting a bond, and such remedy will not be the exclusive remedy for any breach of this Agreement.

 

10.           Independent
Contractor Status. The Consultant shall perform all services under this Agreement as an “independent contractor” and not
as an employee of the Company. Nothing contained in this Agreement shall be deemed to constitute the Consultant an employee, co-venturer
or agent of Company, and the Consultant has no authority to obligate the Company by contract or otherwise. Other than the Prorated 2022
Bonus and the Accrued Benefit (as defined in the Employment Agreement), the Consultant is not owed any further compensation from the Company
under the Employment Agreement or otherwise in connection with his employment with the Company.

 

11.           Notices.
All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or three
(3) days after deposit in the United States Post Office, by registered or certified mail (return receipt requested), postage prepaid,
or by the overnight courier service of a nationally-recognized carrier, (a) if to the Consultant, at the last address the Consultant
has filed in writing with the Company and (b) if to the Company, at its principal business offices addressed to the attention of
the President & Chief Executive Officer with a copy simultaneously sent to the Chief Legal Officer. Notices may also be sent
by email (x) to the last known email address of the Consultant or, (y) in the case of Company, the Company email address of
the Chief Executive Officer with a copy simultaneously sent to the Chief Legal Officer at legal@blueprintmedicines.com, in each case with
confirmation of receipt.

 

12.           Pronouns.
Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms,
and the singular forms of nouns and pronouns shall include the plural, and vice versa.

 

13.           Entire
Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement, including, without limitation, the Employment Agreement; provided
that (i) the Restrictive Covenants Agreement and (ii) any equity award agreements and the Amendment Agreement related thereto
entered into by the Company and the Consultant prior to the date hereof, in each case, are expressly preserved.

 

14.           Amendment.
This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.

 

15.           Non-Assignability
of Contract by the Consultant. This Agreement is personal to the Consultant and the Consultant shall not have the right to assign
any of his rights or delegate any of his duties without the express written consent of the Company. Any non-consented-to assignment or
delegation, whether express or implied or by operation of law, shall be void and shall constitute a breach and a default by the Consultant.

 

    	 	- 7 -	 

     

    

 

16.           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without giving
effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction.

 

17.           Successors
and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns,
including any entity with which, or into which, the Company may be merged or consolidated or which may succeed to its assets or business;
provided, however, that the obligations of the Consultant are personal and shall not be assigned by him.

 

18.           Use
of Name. The Consultant consents to the use by the Company of the Consultant’s name on its website, in press releases, company
brochures, offering documents, presentations, reports or other documents in printed or electronic form, and any documents filed with or
submitted to any governmental or regulatory agency or any securities exchange or listing entity; provided, that such materials
or presentations accurately describe the nature of the Consultant’s relationship with or contribution to the Company.

 

19.           Survival.
Section 4 and Sections 6 through 23 shall survive the termination of this Agreement.

  

20.           Section 409A.

 

20.1         To
the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Consultant’s termination of service,
then such payments or benefits shall be payable only upon the Consultant’s “separation from service.” The determination
of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-1(h).

 

20.2         The
parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute
a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended,
as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and
regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

 

20.3         The
Company makes no representation or warranty and shall have no liability to the Consultant or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption
from, or the conditions of, such Section.

 

21.           Formulary
Committee Members. If the Consultant is or becomes a member of formulary committees or assists in developing clinical practice guidelines,
the Consultant shall disclose to the formulary committee or clinical practice guideline committee the existence and nature of his relationship
with the Company. This disclosure obligation will extend for at least two years beyond the termination of this Agreement.

 

    	 	- 8 -	 

     

    

 

22.           Publication;
Publicity. The Consultant may not publish or refer to Inventions, in whole or in part, without the prior express written consent of
the Company. The Consultant will not use the name, logo, trade name, service marks, or trademarks, or any simulation, abbreviation, or
adaptation of same, or the Company or any of its affiliates for publicity, promotion, or other uses without the Company’s prior
written consent.

 

23.           Miscellaneous.

 

23.1         No
delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. No
waiver of any term or condition of this Agreement shall be valid or binding on either party thereto unless the same shall be been mutually
assented to in writing by both parties. The failure of either party to enforce at any time any of the provisions of this Agreement, or
the failure to require at any time performance by the other party of any of the provisions of this Agreement, shall in no way be construed
to be a present or future waiver of such provisions, nor in any way affect the right of either party to enforce each and every such provision
thereafter. The express waiver by either party of any provision, condition or requirement of this Agreement shall not constitute a waiver
of any future obligation to comply with such provision, condition or requirement.

  

23.2         The
captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance
of any section of this Agreement.

 

23.3         In
the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable in whole or in part, (a) such
provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the
intent of the parties, within the limits of applicable law and (b) the validity, legality and enforceability of the remaining provisions
shall in no way be affected or impaired thereby.

 

23.4         This
Agreement has been prepared jointly and will not be strictly construed against either party.

 

23.5         This
Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including portable document format (“.pdf”)
or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered
will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Remainder of Page Intentionally Left Blank]

  

    	 	- 9 -	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Consulting Agreement effective as of the Effective Date.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 
	 	 
	 	By:	/s/ Kate Haviland
	 	Name: Kathryn Haviland
	 	Title: President & Chief
    Executive Officer
	 	Date:	   12/23/2022
	 	 
	 	 
	 	CONSULTANT
	 	 
	 	 
	 	/s/ Jeff Albers
	 	Jeffrey W. Albers
	 	Date:	   12/23/2022

 

[Signature
Page to Consulting Agreement]

 

     

     

    

 

Exhibit A

 

Consulting Services

 

In addition to the time and responsibilities reasonably
expected of members of the Board and of the Chairman of the Board (which, for the avoidance of doubt, are not subject to this Agreement),
provide the Company with strategic advice and services upon reasonable request by the Chief Executive Officer of the Company (“CEO”)
which may include, without limitation, matters related to implementation of the Company’s long-term Technical Operations strategy,
alliance management operational excellence, geographic expansion strategy implementation, commercial operational excellence, and buy-side
and sell-side investor relations strategy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]